ID   SRC_HUMAN               Reviewed;         536 AA.
AC   P12931; E1P5V4; Q76P87; Q86VB9; Q9H5A8;
DT   01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   12-OCT-2022, entry version 260.
DE   RecName: Full=Proto-oncogene tyrosine-protein kinase Src {ECO:0000305};
DE            EC=2.7.10.2 {ECO:0000269|PubMed:14632929, ECO:0000269|PubMed:19307596, ECO:0000269|PubMed:21036157, ECO:0000269|PubMed:7929427, ECO:0000269|PubMed:8759729, ECO:0000269|PubMed:9571170};
DE   AltName: Full=Proto-oncogene c-Src;
DE   AltName: Full=pp60c-src;
DE            Short=p60-Src;
GN   Name=SRC {ECO:0000312|HGNC:HGNC:11283}; Synonyms=SRC1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D.,
RA   Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G.,
RA   Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E.,
RA   Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D.,
RA   Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M.,
RA   Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D.,
RA   Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M.,
RA   Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A.,
RA   Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L.,
RA   Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L.,
RA   Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-185 (ISOFORM 1).
RX   PubMed=3299057; DOI=10.1128/mcb.7.5.1978-1983.1987;
RA   Tanaka A., Gibbs C.P., Arthur R.R., Anderson S.K., Kung H.-J., Fujita D.J.;
RT   "DNA sequence encoding the amino-terminal region of the human c-src
RT   protein: implications of sequence divergence among src-type kinase
RT   oncogenes.";
RL   Mol. Cell. Biol. 7:1978-1983(1987).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 186-536 (ISOFORM 1).
RX   PubMed=2582238; DOI=10.1128/mcb.5.5.1122-1129.1985;
RA   Anderson S.K., Gibbs C.P., Tanaka A., Kung H.-J., Fujita D.J.;
RT   "Human cellular src gene: nucleotide sequence and derived amino acid
RT   sequence of the region coding for the carboxy-terminal two-thirds of pp60c-
RT   src.";
RL   Mol. Cell. Biol. 5:1122-1129(1985).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 98-139 (ISOFORM 2).
RX   PubMed=2681803; DOI=10.1002/jnr.490240113;
RA   Pyper J.M., Bolen J.B.;
RT   "Neuron-specific splicing of C-SRC RNA in human brain.";
RL   J. Neurosci. Res. 24:89-96(1989).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 376-536 (ISOFORM 1).
RX   PubMed=2581127; DOI=10.1128/mcb.5.4.831-838.1985;
RA   Parker R.C., Mardon G., Lebo R.V., Varmus H.E., Bishop J.M.;
RT   "Isolation of duplicated human c-src genes located on chromosomes 1 and
RT   20.";
RL   Mol. Cell. Biol. 5:831-838(1985).
RN   [8]
RP   PHOSPHORYLATION AT TYR-419.
RX   PubMed=6273838; DOI=10.1073/pnas.78.10.6013;
RA   Smart J.E., Oppermann H., Czernilofsky A.P., Purchio A.F., Erikson R.L.,
RA   Bishop J.M.;
RT   "Characterization of sites for tyrosine phosphorylation in the transforming
RT   protein of Rous sarcoma virus (pp60v-src) and its normal cellular homologue
RT   (pp60c-src).";
RL   Proc. Natl. Acad. Sci. U.S.A. 78:6013-6017(1981).
RN   [9]
RP   ROLE IN TUMOR TISSUES.
RX   PubMed=3093483; DOI=10.1016/s0021-9258(18)67084-x;
RA   Rosen N., Bolen J.B., Schwartz A.M., Cohen P., DeSeau V., Israel M.A.;
RT   "Analysis of pp60c-src protein kinase activity in human tumor cell lines
RT   and tissues.";
RL   J. Biol. Chem. 261:13754-13759(1986).
RN   [10]
RP   ROLE IN COLON CARCINOMA.
RX   PubMed=2498394; DOI=10.1172/jci114113;
RA   Cartwright C.A., Kamps M.P., Meisler A.I., Pipas J.M., Eckhart W.;
RT   "pp60c-src activation in human colon carcinoma.";
RL   J. Clin. Invest. 83:2025-2033(1989).
RN   [11]
RP   ALTERNATIVE SPLICING, AND DEVELOPMENTAL STAGE (ISOFORMS 1; 2 AND 3).
RX   PubMed=1691439; DOI=10.1128/mcb.10.5.2035-2040.1990;
RA   Pyper J.M., Bolen J.B.;
RT   "Identification of a novel neuronal C-SRC exon expressed in human brain.";
RL   Mol. Cell. Biol. 10:2035-2040(1990).
RN   [12]
RP   TISSUE SPECIFICITY (ISOFORMS 1; 2 AND 3).
RX   PubMed=8319227;
RA   Matsunaga T., Shirasawa H., Tanabe M., Ohnuma N., Takahashi H., Simizu B.;
RT   "Expression of alternatively spliced src messenger RNAs related to neuronal
RT   differentiation in human neuroblastomas.";
RL   Cancer Res. 53:3179-3185(1993).
RN   [13]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-530, AND MYRISTOYLATION AT
RP   GLY-2.
RX   PubMed=7525268; DOI=10.1002/j.1460-2075.1994.tb06800.x;
RA   Kaplan K.B., Bibbins K.B., Swedlow J.R., Arnaud M., Morgan D.O.,
RA   Varmus H.E.;
RT   "Association of the amino-terminal half of c-Src with focal adhesions
RT   alters their properties and is regulated by phosphorylation of tyrosine
RT   527.";
RL   EMBO J. 13:4745-4756(1994).
RN   [14]
RP   CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND PHOSPHORYLATION AT TYR-530.
RX   PubMed=7929427; DOI=10.1016/s0021-9258(18)47102-5;
RA   Stover D.R., Liebetanz J., Lydon N.B.;
RT   "Cdc2-mediated modulation of pp60c-src activity.";
RL   J. Biol. Chem. 269:26885-26889(1994).
RN   [15]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=7853507; DOI=10.1128/jvi.69.3.1699-1713.1995;
RA   David-Pfeuty T., Nouvian-Dooghe Y.;
RT   "Highly specific antibody to Rous sarcoma virus src gene product recognizes
RT   nuclear and nucleolar antigens in human cells.";
RL   J. Virol. 69:1699-1713(1995).
RN   [16]
RP   INTERACTION WITH CEACAM1.
RX   PubMed=7478590;
RA   Bruemmer J., Neumaier M., Goepfert C., Wagener C.;
RT   "Association of pp60c-src with biliary glycoprotein (CD66a), an adhesion
RT   molecule of the carcinoembryonic antigen family downregulated in colorectal
RT   carcinomas.";
RL   Oncogene 11:1649-1655(1995).
RN   [17]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND INTERACTION WITH
RP   FCAMR.
RX   PubMed=8759729;
RA   Rabinowich H., Manciulea M., Metes D., Sulica A., Herberman R.B.,
RA   Corey S.J., Whiteside T.L.;
RT   "Physical and functional association of Fc mu receptor on human natural
RT   killer cells with the zeta- and Fc epsilon RI gamma-chains and with src
RT   family protein tyrosine kinases.";
RL   J. Immunol. 157:1485-1491(1996).
RN   [18]
RP   FUNCTION IN HGF SIGNALING PATHWAY.
RX   PubMed=8755529; DOI=10.1073/pnas.93.15.7644;
RA   Grano M., Galimi F., Zambonin G., Colucci S., Cottone E., Zallone A.Z.,
RA   Comoglio P.M.;
RT   "Hepatocyte growth factor is a coupling factor for osteoclasts and
RT   osteoblasts in vitro.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:7644-7648(1996).
RN   [19]
RP   CATALYTIC ACTIVITY, AND ACTIVITY REGULATION.
RX   PubMed=9571170; DOI=10.1006/bbrc.1998.8452;
RA   Yang E.B., Zhang K., Cheng L.Y., Mack P.;
RT   "Butein, a specific protein tyrosine kinase inhibitor.";
RL   Biochem. Biophys. Res. Commun. 245:435-438(1998).
RN   [20]
RP   INTERACTION WITH RACK1.
RX   PubMed=9584165; DOI=10.1128/mcb.18.6.3245;
RA   Chang B.Y., Conroy K.B., Machleder E.M., Cartwright C.A.;
RT   "RACK1, a receptor for activated C kinase and a homolog of the beta subunit
RT   of G proteins, inhibits activity of src tyrosine kinases and growth of NIH
RT   3T3 cells.";
RL   Mol. Cell. Biol. 18:3245-3256(1998).
RN   [21]
RP   INTERACTION WITH ADRB2 AND ARRB1.
RX   PubMed=9924018; DOI=10.1126/science.283.5402.655;
RA   Luttrell L.M., Ferguson S.S.G., Daaka Y., Miller W.E., Maudsley S.,
RA   Della Rocca G.J., Lin F.-T., Kawakatsu H., Owada K., Luttrell D.K.,
RA   Caron M.G., Lefkowitz R.J.;
RT   "Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein
RT   kinase complexes.";
RL   Science 283:655-661(1999).
RN   [22]
RP   INTERACTION WITH ARRB1 AND ARRB2.
RX   PubMed=10753943; DOI=10.1074/jbc.275.15.11312;
RA   Miller W.E., Maudsley S., Ahn S., Khan K.D., Luttrell L.M., Lefkowitz R.J.;
RT   "beta-arrestin1 interacts with the catalytic domain of the tyrosine kinase
RT   c-SRC. Role of beta-arrestin1-dependent targeting of c-SRC in receptor
RT   endocytosis.";
RL   J. Biol. Chem. 275:11312-11319(2000).
RN   [23]
RP   INTERACTION WITH RALGPS1.
RX   PubMed=10747847; DOI=10.1074/jbc.c000085200;
RA   Rebhun J.F., Chen H., Quilliam L.A.;
RT   "Identification and characterization of a new family of guanine nucleotide
RT   exchange factors for the ras-related GTPase Ral.";
RL   J. Biol. Chem. 275:13406-13410(2000).
RN   [24]
RP   FUNCTION IN PHOSPHORYLATION OF RASA1 AND RASGRF1.
RX   PubMed=11389730; DOI=10.1046/j.1432-1327.2001.02230.x;
RA   Giglione C., Gonfloni S., Parmeggiani A.;
RT   "Differential actions of p60c-Src and Lck kinases on the Ras regulators
RT   p120-GAP and GDP/GTP exchange factor CDC25Mm.";
RL   Eur. J. Biochem. 268:3275-3283(2001).
RN   [25]
RP   INTERACTION WITH MUC1.
RX   PubMed=11152665; DOI=10.1074/jbc.c000754200;
RA   Li Y., Kuwahara H., Ren J., Wen G., Kufe D.;
RT   "The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1
RT   carcinoma-associated antigen with GSK3 beta and beta-catenin.";
RL   J. Biol. Chem. 276:6061-6064(2001).
RN   [26]
RP   INTERACTION WITH RACK1.
RX   PubMed=11279199; DOI=10.1074/jbc.m101375200;
RA   Chang B.Y., Chiang M., Cartwright C.A.;
RT   "The interaction of Src and RACK1 is enhanced by activation of protein
RT   kinase C and tyrosine phosphorylation of RACK1.";
RL   J. Biol. Chem. 276:20346-20356(2001).
RN   [27]
RP   INTERACTION WITH HEV ORF3 PROTEIN (MICROBIAL INFECTION).
RX   PubMed=11518702; DOI=10.1074/jbc.m101546200;
RA   Korkaya H., Jameel S., Gupta D., Tyagi S., Kumar R., Zafrullah M.,
RA   Mazumdar M., Lal S.K., Xiaofang L., Sehgal D., Das S.R., Sahal D.;
RT   "The ORF3 protein of hepatitis E virus binds to Src homology 3 domains and
RT   activates MAPK.";
RL   J. Biol. Chem. 276:42389-42400(2001).
RN   [28]
RP   INTERACTION WITH CAV2.
RX   PubMed=12091389; DOI=10.1074/jbc.m204367200;
RA   Lee H., Park D.S., Wang X.B., Scherer P.E., Schwartz P.E., Lisanti M.P.;
RT   "Src-induced phosphorylation of caveolin-2 on tyrosine 19. Phospho-
RT   caveolin-2 (Tyr(P)19) is localized near focal adhesions, remains associated
RT   with lipid rafts/caveolae, but no longer forms a high molecular mass
RT   hetero-oligomer with caveolin-1.";
RL   J. Biol. Chem. 277:34556-34567(2002).
RN   [29]
RP   RETRACTED PAPER.
RX   PubMed=12415108; DOI=10.1073/pnas.192569699;
RA   Wong C.-W., McNally C., Nickbarg E., Komm B.S., Cheskis B.J.;
RT   "Estrogen receptor-interacting protein that modulates its nongenomic
RT   activity-crosstalk with Src/Erk phosphorylation cascade.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:14783-14788(2002).
RN   [30]
RP   RETRACTION NOTICE OF PUBMED:12415108.
RX   PubMed=19666546; DOI=10.1073/pnas.0908685106;
RA   Wong C.W., McNally C., Nickbarg E., Komm B.S., Cheskis B.J.;
RL   Proc. Natl. Acad. Sci. U.S.A. 106:14180-14180(2009).
RN   [31]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12615910; DOI=10.1083/jcb.200209098;
RA   Miyazaki T., Neff L., Tanaka S., Horne W.C., Baron R.;
RT   "Regulation of cytochrome c oxidase activity by c-Src in osteoclasts.";
RL   J. Cell Biol. 160:709-718(2003).
RN   [32]
RP   INTERACTION WITH EPHB1.
RX   PubMed=12925710; DOI=10.1083/jcb.200302073;
RA   Vindis C., Cerretti D.P., Daniel T.O., Huynh-Do U.;
RT   "EphB1 recruits c-Src and p52Shc to activate MAPK/ERK and promote
RT   chemotaxis.";
RL   J. Cell Biol. 162:661-671(2003).
RN   [33]
RP   CATALYTIC ACTIVITY, AND ACTIVITY REGULATION.
RX   PubMed=14632929; DOI=10.1046/j.1399-3011.2003.00094.x;
RA   Kamath J.R., Liu R., Enstrom A.M., Lou Q., Lam K.S.;
RT   "Development and characterization of potent and specific peptide inhibitors
RT   of p60c-src protein tyrosine kinase using pseudosubstrate-based inhibitor
RT   design approach.";
RL   J. Pept. Res. 62:260-268(2003).
RN   [34]
RP   FUNCTION IN PHOSPHORYLATION OF PDPK1, AND INTERACTION WITH PTK2B/PYK2.
RX   PubMed=14585963; DOI=10.1128/mcb.23.22.8019-8029.2003;
RA   Taniyama Y., Weber D.S., Rocic P., Hilenski L., Akers M.L., Park J.,
RA   Hemmings B.A., Alexander R.W., Griendling K.K.;
RT   "Pyk2- and Src-dependent tyrosine phosphorylation of PDK1 regulates focal
RT   adhesions.";
RL   Mol. Cell. Biol. 23:8019-8029(2003).
RN   [35]
RP   INTERACTION WITH CAV2.
RX   PubMed=15504032; DOI=10.1021/bi049295+;
RA   Wang X.B., Lee H., Capozza F., Marmon S., Sotgia F., Brooks J.W.,
RA   Campos-Gonzalez R., Lisanti M.P.;
RT   "Tyrosine phosphorylation of caveolin-2 at residue 27: differences in the
RT   spatial and temporal behavior of phospho-Cav-2 (pY19 and pY27).";
RL   Biochemistry 43:13694-13706(2004).
RN   [36]
RP   INTERACTION WITH PELP1.
RX   PubMed=14963108; DOI=10.1210/me.2003-0335;
RA   Barletta F., Wong C.-W., McNally C., Komm B.S., Katzenellenbogen B.,
RA   Cheskis B.J.;
RT   "Characterization of the interactions of estrogen receptor and MNAR in the
RT   activation of cSrc.";
RL   Mol. Endocrinol. 18:1096-1108(2004).
RN   [37]
RP   INTERACTION WITH CBCLC, PHOSPHORYLATION AT TYR-419, AND MUTAGENESIS OF
RP   LYS-298.
RX   PubMed=14661060; DOI=10.1038/sj.onc.1207298;
RA   Kim M., Tezuka T., Tanaka K., Yamamoto T.;
RT   "Cbl-c suppresses v-Src-induced transformation through ubiquitin-dependent
RT   protein degradation.";
RL   Oncogene 23:1645-1655(2004).
RN   [38]
RP   INTERACTION WITH CDCP1.
RX   PubMed=15851033; DOI=10.1016/j.cell.2005.02.019;
RA   Benes C.H., Wu N., Elia A.E.H., Dharia T., Cantley L.C., Soltoff S.P.;
RT   "The C2 domain of PKCdelta is a phosphotyrosine binding domain.";
RL   Cell 121:271-280(2005).
RN   [39]
RP   FUNCTION IN PHOSPHORYLATION OF DDR2.
RX   PubMed=16186108; DOI=10.1074/jbc.m506921200;
RA   Yang K., Kim J.H., Kim H.J., Park I.S., Kim I.Y., Yang B.S.;
RT   "Tyrosine 740 phosphorylation of discoidin domain receptor 2 by Src
RT   stimulates intramolecular autophosphorylation and Shc signaling complex
RT   formation.";
RL   J. Biol. Chem. 280:39058-39066(2005).
RN   [40]
RP   INTERACTION WITH TOM1L2.
RX   PubMed=16479011; DOI=10.1128/mcb.26.5.1932-1947.2006;
RA   Franco M., Furstoss O., Simon V., Benistant C., Hong W.J., Roche S.;
RT   "The adaptor protein Tom1L1 is a negative regulator of Src mitogenic
RT   signaling induced by growth factors.";
RL   Mol. Cell. Biol. 26:1932-1947(2006).
RN   [41]
RP   INTERACTION WITH TGFB1I1.
RX   PubMed=17202804; DOI=10.1159/000098402;
RA   Maudsley S., Davidson L., Pawson A.J., Freestone S.H.,
RA   Lopez de Maturana R., Thomson A.A., Millar R.P.;
RT   "Gonadotropin-releasing hormone functionally antagonizes testosterone
RT   activation of the human androgen receptor in prostate cells through focal
RT   adhesion complexes involving Hic-5.";
RL   Neuroendocrinology 84:285-300(2006).
RN   [42]
RP   INTERACTION WITH AMOTL2.
RX   PubMed=17293535; DOI=10.1242/dev.02782;
RA   Huang H., Lu F.I., Jia S., Meng S., Cao Y., Wang Y., Ma W., Yin K., Wen Z.,
RA   Peng J., Thisse C., Thisse B., Meng A.;
RT   "Amotl2 is essential for cell movements in zebrafish embryo and regulates
RT   c-Src translocation.";
RL   Development 134:979-988(2007).
RN   [43]
RP   INTERACTION WITH SRCIN1.
RX   PubMed=17525734; DOI=10.1038/sj.emboj.7601724;
RA   Di Stefano P., Damiano L., Cabodi S., Aramu S., Tordella L., Praduroux A.,
RA   Piva R., Cavallo F., Forni G., Silengo L., Tarone G., Turco E.,
RA   Defilippi P.;
RT   "p140Cap protein suppresses tumour cell properties, regulating Csk and Src
RT   kinase activity.";
RL   EMBO J. 26:2843-2855(2007).
RN   [44]
RP   FUNCTION.
RX   PubMed=18586953; DOI=10.1152/ajplung.90282.2008;
RA   Jeulin C., Seltzer V., Bailbe D., Andreau K., Marano F.;
RT   "EGF mediates calcium-activated chloride channel activation in the human
RT   bronchial epithelial cell line 16HBE14o-: involvement of tyrosine kinase
RT   p60c-src.";
RL   Am. J. Physiol. 295:L489-L496(2008).
RN   [45]
RP   INTERACTION WITH PDPK1.
RX   PubMed=18024423; DOI=10.1074/jbc.m706361200;
RA   Yang K.J., Shin S., Piao L., Shin E., Li Y., Park K.A., Byun H.S., Won M.,
RA   Hong J., Kweon G.R., Hur G.M., Seok J.H., Chun T., Brazil D.P.,
RA   Hemmings B.A., Park J.;
RT   "Regulation of 3-phosphoinositide-dependent protein kinase-1 (PDK1) by Src
RT   involves tyrosine phosphorylation of PDK1 and Src homology 2 domain
RT   binding.";
RL   J. Biol. Chem. 283:1480-1491(2008).
RN   [46]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-17, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [47]
RP   INTERACTION WITH PTK2/FAK1; PI3KR1/2 AND ESR1.
RX   PubMed=18657504; DOI=10.1016/j.molcel.2008.05.025;
RA   Le Romancer M., Treilleux I., Leconte N., Robin-Lespinasse Y., Sentis S.,
RA   Bouchekioua-Bouzaghou K., Goddard S., Gobert-Gosse S., Corbo L.;
RT   "Regulation of estrogen rapid signaling through arginine methylation by
RT   PRMT1.";
RL   Mol. Cell 31:212-221(2008).
RN   [48]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [49]
RP   INTERACTION WITH FASLG.
RX   PubMed=19807924; DOI=10.1186/1471-2172-10-53;
RA   Voss M., Lettau M., Janssen O.;
RT   "Identification of SH3 domain interaction partners of human FasL (CD178) by
RT   phage display screening.";
RL   BMC Immunol. 10:53-53(2009).
RN   [50]
RP   INTERACTION WITH MPP2.
RX   PubMed=19665017; DOI=10.1016/j.yexcr.2009.07.028;
RA   Baumgartner M., Weiss A., Fritzius T., Heinrich J., Moelling K.;
RT   "The PDZ protein MPP2 interacts with c-Src in epithelial cells.";
RL   Exp. Cell Res. 315:2888-2898(2009).
RN   [51]
RP   FUNCTION, AND INTERACTION WITH TRAF3; MAVS; DDX58 AND TBK1.
RX   PubMed=19419966; DOI=10.1074/jbc.m808233200;
RA   Johnsen I.B., Nguyen T.T., Bergstroem B., Fitzgerald K.A., Anthonsen M.W.;
RT   "The tyrosine kinase c-Src enhances RIG-I (retinoic acid-inducible gene I)-
RT   elicited antiviral signaling.";
RL   J. Biol. Chem. 284:19122-19131(2009).
RN   [52]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH PDLIM4, SUBCELLULAR
RP   LOCATION, PHOSPHORYLATION AT TYR-419 AND TYR-530, AND MUTAGENESIS OF
RP   PRO-302; PRO-307 AND TYR-419.
RX   PubMed=19307596; DOI=10.1083/jcb.200810155;
RA   Zhang Y., Tu Y., Zhao J., Chen K., Wu C.;
RT   "Reversion-induced LIM interaction with Src reveals a novel Src
RT   inactivation cycle.";
RL   J. Cell Biol. 184:785-792(2009).
RN   [53]
RP   PHOSPHORYLATION AT TYR-419, AND DEPHOSPHORYLATION AT TYR-419 BY PTPRJ.
RX   PubMed=18936167; DOI=10.1128/mcb.01374-08;
RA   Chabot C., Spring K., Gratton J.P., Elchebly M., Royal I.;
RT   "New role for the protein tyrosine phosphatase DEP-1 in Akt activation and
RT   endothelial cell survival.";
RL   Mol. Cell. Biol. 29:241-253(2009).
RN   [54]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-17 AND TYR-530, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [55]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [56]
RP   CATALYTIC ACTIVITY, AND ACTIVITY REGULATION.
RX   PubMed=21036157; DOI=10.1016/j.bbrc.2010.10.101;
RA   Yao X., Balamurugan P., Arvey A., Leslie C., Zhang L.;
RT   "Heme controls the regulation of protein tyrosine kinases Jak2 and Src.";
RL   Biochem. Biophys. Res. Commun. 403:30-35(2010).
RN   [57]
RP   FUNCTION, AND INTERACTION WITH RUNX3.
RX   PubMed=20100835; DOI=10.1074/jbc.m109.071381;
RA   Goh Y.M., Cinghu S., Hong E.T., Lee Y.S., Kim J.H., Jang J.W., Li Y.H.,
RA   Chi X.Z., Lee K.S., Wee H., Ito Y., Oh B.C., Bae S.C.;
RT   "Src kinase phosphorylates RUNX3 at tyrosine residues and localizes the
RT   protein in the cytoplasm.";
RL   J. Biol. Chem. 285:10122-10129(2010).
RN   [58]
RP   FUNCTION IN CBLC PHOSPHORYLATION.
RX   PubMed=20525694; DOI=10.1074/jbc.m109.091157;
RA   Ryan P.E., Sivadasan-Nair N., Nau M.M., Nicholas S., Lipkowitz S.;
RT   "The N terminus of Cbl-c regulates ubiquitin ligase activity by modulating
RT   affinity for the ubiquitin-conjugating enzyme.";
RL   J. Biol. Chem. 285:23687-23698(2010).
RN   [59]
RP   INTERACTION WITH NDFIP1 AND NDFIP2.
RX   PubMed=20534535; DOI=10.1073/pnas.0911714107;
RA   Mund T., Pelham H.R.;
RT   "Regulation of PTEN/Akt and MAP kinase signaling pathways by the ubiquitin
RT   ligase activators Ndfip1 and Ndfip2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:11429-11434(2010).
RN   [60]
RP   FUNCTION, AND INTERACTION WITH TNK2.
RX   PubMed=21309750; DOI=10.1042/bj20102156;
RA   Chan W., Sit S.T., Manser E.;
RT   "The Cdc42-associated kinase ACK1 is not auto-inhibited but requires Src
RT   for activation.";
RL   Biochem. J. 435:355-364(2011).
RN   [61]
RP   PHOSPHORYLATION AT SER-75.
RX   PubMed=21442427; DOI=10.1007/s00018-011-0638-1;
RA   Pan Q., Qiao F., Gao C., Norman B., Optican L., Zelenka P.S.;
RT   "Cdk5 targets active Src for ubiquitin-dependent degradation by
RT   phosphorylating Src(S75).";
RL   Cell. Mol. Life Sci. 68:3425-3436(2011).
RN   [62]
RP   INTERACTION WITH PRR7.
RX   PubMed=21460222; DOI=10.1074/jbc.m110.175117;
RA   Hrdinka M., Draber P., Stepanek O., Ormsby T., Otahal P., Angelisova P.,
RA   Brdicka T., Paces J., Horejsi V., Drbal K.;
RT   "PRR7 is a transmembrane adaptor protein expressed in activated T cells
RT   involved in regulation of T cell receptor signaling and apoptosis.";
RL   J. Biol. Chem. 286:19617-19629(2011).
RN   [63]
RP   FUNCTION IN FOCAL ADHESION DYNAMICS, AND INTERACTION WITH PTK2/FAK1 AND
RP   DNM2.
RX   PubMed=21411625; DOI=10.1091/mbc.e10-09-0785;
RA   Wang Y., Cao H., Chen J., McNiven M.A.;
RT   "A direct interaction between the large GTPase dynamin-2 and FAK regulates
RT   focal adhesion dynamics in response to active Src.";
RL   Mol. Biol. Cell 22:1529-1538(2011).
RN   [64]
RP   IDENTIFICATION IN A COMPLEX WITH PTPRA; BCAR1 AND BCAR3, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=22801373; DOI=10.1128/mcb.00214-12;
RA   Sun G., Cheng S.Y., Chen M., Lim C.J., Pallen C.J.;
RT   "Protein tyrosine phosphatase alpha phosphotyrosyl-789 binds BCAR3 to
RT   position Cas for activation at integrin-mediated focal adhesions.";
RL   Mol. Cell. Biol. 32:3776-3789(2012).
RN   [65]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-17 AND SER-75, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [66]
RP   FUNCTION IN PHOSPHORYLATION OF BCAR1.
RX   PubMed=22710723; DOI=10.1038/onc.2012.220;
RA   Zhang P., Guo A., Possemato A., Wang C., Beard L., Carlin C.,
RA   Markowitz S.D., Polakiewicz R.D., Wang Z.;
RT   "Identification and functional characterization of p130Cas as a substrate
RT   of protein tyrosine phosphatase nonreceptor 14.";
RL   Oncogene 32:2087-2095(2013).
RN   [67]
RP   INTERACTION WITH TRAP1.
RX   PubMed=23564345; DOI=10.1073/pnas.1220659110;
RA   Yoshida S., Tsutsumi S., Muhlebach G., Sourbier C., Lee M.J., Lee S.,
RA   Vartholomaiou E., Tatokoro M., Beebe K., Miyajima N., Mohney R.P., Chen Y.,
RA   Hasumi H., Xu W., Fukushima H., Nakamura K., Koga F., Kihara K., Trepel J.,
RA   Picard D., Neckers L.;
RT   "Molecular chaperone TRAP1 regulates a metabolic switch between
RT   mitochondrial respiration and aerobic glycolysis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:E1604-E1612(2013).
RN   [68]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-17, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [69]
RP   FUNCTION, PHOSPHORYLATION AT TYR-419, AND INTERACTION WITH IL6ST.
RX   PubMed=25731159; DOI=10.1038/nature14228;
RA   Taniguchi K., Wu L.W., Grivennikov S.I., de Jong P.R., Lian I., Yu F.X.,
RA   Wang K., Ho S.B., Boland B.S., Chang J.T., Sandborn W.J., Hardiman G.,
RA   Raz E., Maehara Y., Yoshimura A., Zucman-Rossi J., Guan K.L., Karin M.;
RT   "A gp130-Src-YAP module links inflammation to epithelial regeneration.";
RL   Nature 519:57-62(2015).
RN   [70]
RP   PHOSPHORYLATION AT TYR-419 AND TYR-530, INVOLVEMENT IN THC6, VARIANT THC6
RP   LYS-527, AND CHARACTERIZATION OF VARIANT THC6 LYS-527.
RX   PubMed=26936507; DOI=10.1126/scitranslmed.aad7666;
RG   BRIDGE-BPD Consortium;
RA   Turro E., Greene D., Wijgaerts A., Thys C., Lentaigne C., Bariana T.K.,
RA   Westbury S.K., Kelly A.M., Selleslag D., Stephens J.C., Papadia S.,
RA   Simeoni I., Penkett C.J., Ashford S., Attwood A., Austin S., Bakchoul T.,
RA   Collins P., Deevi S.V., Favier R., Kostadima M., Lambert M.P., Mathias M.,
RA   Millar C.M., Peerlinck K., Perry D.J., Schulman S., Whitehorn D.,
RA   Wittevrongel C., De Maeyer M., Rendon A., Gomez K., Erber W.N.,
RA   Mumford A.D., Nurden P., Stirrups K., Bradley J.R., Raymond F.L.,
RA   Laffan M.A., Van Geet C., Richardson S., Freson K., Ouwehand W.H.;
RT   "A dominant gain-of-function mutation in universal tyrosine kinase SRC
RT   causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies.";
RL   Sci. Transl. Med. 8:328RA30-328RA30(2016).
RN   [71]
RP   INTERACTION WITH P85.
RX   PubMed=28903391; DOI=10.18632/oncotarget.18973;
RA   Lu Y., Zheng X., Hu W., Bian S., Zhang Z., Tao D., Liu Y., Ma Y.;
RT   "Cancer/testis antigen PIWIL2 suppresses circadian rhythms by regulating
RT   the stability and activity of BMAL1 and CLOCK.";
RL   Oncotarget 8:54913-54924(2017).
RN   [72]
RP   REVIEW ON FUNCTION.
RX   PubMed=8672527; DOI=10.1016/0304-419x(96)00003-0;
RA   Brown M.T., Cooper J.A.;
RT   "Regulation, substrates and functions of src.";
RL   Biochim. Biophys. Acta 1287:121-149(1996).
RN   [73]
RP   REVIEW ON FUNCTION.
RX   PubMed=9442882; DOI=10.1146/annurev.cellbio.13.1.513;
RA   Thomas S.M., Brugge J.S.;
RT   "Cellular functions regulated by Src family kinases.";
RL   Annu. Rev. Cell Dev. Biol. 13:513-609(1997).
RN   [74]
RP   REVIEW ON FUNCTION.
RX   PubMed=11964124; DOI=10.1007/s00018-002-8438-2;
RA   Ma Y.C., Huang X.Y.;
RT   "Novel regulation and function of Src tyrosine kinase.";
RL   Cell. Mol. Life Sci. 59:456-462(2002).
RN   [75]
RP   INTERACTION WITH HCV NON-STRUCTURAL PROTEIN 5A (MICROBIAL INFECTION).
RX   PubMed=30862675; DOI=10.1074/jbc.ra119.007656;
RA   Klinker S., Stindt S., Gremer L., Bode J.G., Gertzen C.G.W., Gohlke H.,
RA   Weiergraeber O.H., Hoffmann S., Willbold D.;
RT   "Phosphorylated tyrosine 93 of hepatitis C virus nonstructural protein 5A
RT   is essential for interaction with host c-Src and efficient viral
RT   replication.";
RL   J. Biol. Chem. 294:7388-7402(2019).
RN   [76]
RP   INTERACTION WITH HNRNPA2B1.
RX   PubMed=31320558; DOI=10.1126/science.aav0758;
RA   Wang L., Wen M., Cao X.;
RT   "Nuclear hnRNPA2B1 initiates and amplifies the innate immune response to
RT   DNA viruses.";
RL   Science 0:0-0(2019).
RN   [77]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 86-536.
RX   PubMed=9024657; DOI=10.1038/385595a0;
RA   Xu W., Harrison S.C., Eck M.J.;
RT   "Three-dimensional structure of the tyrosine kinase c-Src.";
RL   Nature 385:595-602(1997).
RN   [78]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 145-249.
RX   PubMed=9174343; DOI=10.1021/bi970019n;
RA   Charifson P.S., Shewchuk L.M., Rocque W., Hummel C.W., Jordan S.R.,
RA   Mohr C., Pacofsky G.J., Peel M.R., Rodriguez M., Sternbach D.D.,
RA   Consler T.G.;
RT   "Peptide ligands of pp60(c-src) SH2 domains: a thermodynamic and structural
RT   study.";
RL   Biochemistry 36:6283-6293(1997).
RN   [79]
RP   STRUCTURE BY NMR OF 204-249.
RX   PubMed=7532003; DOI=10.1021/bi00007a003;
RA   Xu R.X., Word J.M., Davis D.G., Rink M.J., Willard D.H. Jr.,
RA   Gampe R.T. Jr.;
RT   "Solution structure of the human pp60c-src SH2 domain complexed with a
RT   phosphorylated tyrosine pentapeptide.";
RL   Biochemistry 34:2107-2121(1995).
RN   [80]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 412-424 IN COMPLEX WITH CBLC,
RP   UBIQUITINATION, AND INTERACTION WITH CBLC.
RX   PubMed=22888118; DOI=10.1093/jb/mvs085;
RA   Takeshita K., Tezuka T., Isozaki Y., Yamashita E., Suzuki M., Kim M.,
RA   Yamanashi Y., Yamamoto T., Nakagawa A.;
RT   "Structural flexibility regulates phosphopeptide-binding activity of the
RT   tyrosine kinase binding domain of Cbl-c.";
RL   J. Biochem. 152:487-495(2012).
RN   [81]
RP   VARIANT [LARGE SCALE ANALYSIS] THR-237.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Non-receptor protein tyrosine kinase which is activated
CC       following engagement of many different classes of cellular receptors
CC       including immune response receptors, integrins and other adhesion
CC       receptors, receptor protein tyrosine kinases, G protein-coupled
CC       receptors as well as cytokine receptors. Participates in signaling
CC       pathways that control a diverse spectrum of biological activities
CC       including gene transcription, immune response, cell adhesion, cell
CC       cycle progression, apoptosis, migration, and transformation. Due to
CC       functional redundancy between members of the SRC kinase family,
CC       identification of the specific role of each SRC kinase is very
CC       difficult. SRC appears to be one of the primary kinases activated
CC       following engagement of receptors and plays a role in the activation of
CC       other protein tyrosine kinase (PTK) families. Receptor clustering or
CC       dimerization leads to recruitment of SRC to the receptor complexes
CC       where it phosphorylates the tyrosine residues within the receptor
CC       cytoplasmic domains. Plays an important role in the regulation of
CC       cytoskeletal organization through phosphorylation of specific
CC       substrates such as AFAP1. Phosphorylation of AFAP1 allows the SRC SH2
CC       domain to bind AFAP1 and to localize to actin filaments. Cytoskeletal
CC       reorganization is also controlled through the phosphorylation of
CC       cortactin (CTTN) (Probable). When cells adhere via focal adhesions to
CC       the extracellular matrix, signals are transmitted by integrins into the
CC       cell resulting in tyrosine phosphorylation of a number of focal
CC       adhesion proteins, including PTK2/FAK1 and paxillin (PXN)
CC       (PubMed:21411625). In addition to phosphorylating focal adhesion
CC       proteins, SRC is also active at the sites of cell-cell contact adherens
CC       junctions and phosphorylates substrates such as beta-catenin (CTNNB1),
CC       delta-catenin (CTNND1), and plakoglobin (JUP). Another type of cell-
CC       cell junction, the gap junction, is also a target for SRC, which
CC       phosphorylates connexin-43 (GJA1). SRC is implicated in regulation of
CC       pre-mRNA-processing and phosphorylates RNA-binding proteins such as
CC       KHDRBS1 (Probable). Also plays a role in PDGF-mediated tyrosine
CC       phosphorylation of both STAT1 and STAT3, leading to increased DNA
CC       binding activity of these transcription factors (By similarity).
CC       Involved in the RAS pathway through phosphorylation of RASA1 and
CC       RASGRF1 (PubMed:11389730). Plays a role in EGF-mediated calcium-
CC       activated chloride channel activation (PubMed:18586953). Required for
CC       epidermal growth factor receptor (EGFR) internalization through
CC       phosphorylation of clathrin heavy chain (CLTC and CLTCL1) at 'Tyr-
CC       1477'. Involved in beta-arrestin (ARRB1 and ARRB2) desensitization
CC       through phosphorylation and activation of GRK2, leading to beta-
CC       arrestin phosphorylation and internalization. Has a critical role in
CC       the stimulation of the CDK20/MAPK3 mitogen-activated protein kinase
CC       cascade by epidermal growth factor (Probable). Might be involved not
CC       only in mediating the transduction of mitogenic signals at the level of
CC       the plasma membrane but also in controlling progression through the
CC       cell cycle via interaction with regulatory proteins in the nucleus
CC       (PubMed:7853507). Plays an important role in osteoclastic bone
CC       resorption in conjunction with PTK2B/PYK2. Both the formation of a SRC-
CC       PTK2B/PYK2 complex and SRC kinase activity are necessary for this
CC       function. Recruited to activated integrins by PTK2B/PYK2, thereby
CC       phosphorylating CBL, which in turn induces the activation and
CC       recruitment of phosphatidylinositol 3-kinase to the cell membrane in a
CC       signaling pathway that is critical for osteoclast function
CC       (PubMed:8755529, PubMed:14585963). Promotes energy production in
CC       osteoclasts by activating mitochondrial cytochrome C oxidase
CC       (PubMed:12615910). Phosphorylates DDR2 on tyrosine residues, thereby
CC       promoting its subsequent autophosphorylation (PubMed:16186108).
CC       Phosphorylates RUNX3 and COX2 on tyrosine residues, TNK2 on 'Tyr-284'
CC       and CBL on 'Tyr-731' (PubMed:20100835, PubMed:21309750). Enhances
CC       DDX58/RIG-I-elicited antiviral signaling (PubMed:19419966).
CC       Phosphorylates PDPK1 at 'Tyr-9', 'Tyr-373' and 'Tyr-376'
CC       (PubMed:14585963). Phosphorylates BCAR1 at 'Tyr-128' (PubMed:22710723).
CC       Phosphorylates CBLC at multiple tyrosine residues, phosphorylation at
CC       'Tyr-341' activates CBLC E3 activity (PubMed:20525694). Phosphorylates
CC       synaptic vesicle protein synaptophysin (SYP) (By similarity). Involved
CC       in anchorage-independent cell growth (PubMed:19307596). Required for
CC       podosome formation (By similarity). Mediates IL6 signaling by
CC       activating YAP1-NOTCH pathway to induce inflammation-induced epithelial
CC       regeneration (PubMed:25731159). {ECO:0000250|UniProtKB:P05480,
CC       ECO:0000250|UniProtKB:Q9WUD9, ECO:0000269|PubMed:11389730,
CC       ECO:0000269|PubMed:12615910, ECO:0000269|PubMed:14585963,
CC       ECO:0000269|PubMed:16186108, ECO:0000269|PubMed:18586953,
CC       ECO:0000269|PubMed:19307596, ECO:0000269|PubMed:19419966,
CC       ECO:0000269|PubMed:20100835, ECO:0000269|PubMed:20525694,
CC       ECO:0000269|PubMed:21309750, ECO:0000269|PubMed:21411625,
CC       ECO:0000269|PubMed:22710723, ECO:0000269|PubMed:25731159,
CC       ECO:0000269|PubMed:7853507, ECO:0000269|PubMed:8755529,
CC       ECO:0000269|PubMed:8759729, ECO:0000305|PubMed:11964124,
CC       ECO:0000305|PubMed:8672527, ECO:0000305|PubMed:9442882}.
CC   -!- FUNCTION: [Isoform 1]: Non-receptor protein tyrosine kinase which
CC       phosphorylates synaptophysin with high affinity.
CC       {ECO:0000250|UniProtKB:Q9WUD9}.
CC   -!- FUNCTION: [Isoform 2]: Non-receptor protein tyrosine kinase which shows
CC       higher basal kinase activity than isoform 1, possibly due to weakened
CC       intramolecular interactions which enhance autophosphorylation of Tyr-
CC       419 and subsequent activation (By similarity). The SH3 domain shows
CC       reduced affinity with the linker sequence between the SH2 and kinase
CC       domains which may account for the increased basal activity (By
CC       similarity). Displays altered substrate specificity compared to isoform
CC       1, showing weak affinity for synaptophysin and for peptide substrates
CC       containing class I or class II SH3 domain-binding motifs (By
CC       similarity). Plays a role in L1CAM-mediated neurite elongation,
CC       possibly by acting downstream of L1CAM to drive cytoskeletal
CC       rearrangements involved in neurite outgrowth (By similarity).
CC       {ECO:0000250|UniProtKB:Q9WUD9}.
CC   -!- FUNCTION: [Isoform 3]: Non-receptor protein tyrosine kinase which shows
CC       higher basal kinase activity than isoform 1, possibly due to weakened
CC       intramolecular interactions which enhance autophosphorylation of Tyr-
CC       419 and subsequent activation (By similarity). The SH3 domain shows
CC       reduced affinity with the linker sequence between the SH2 and kinase
CC       domains which may account for the increased basal activity (By
CC       similarity). Displays altered substrate specificity compared to isoform
CC       1, showing weak affinity for synaptophysin and for peptide substrates
CC       containing class I or class II SH3 domain-binding motifs (By
CC       similarity). Plays a role in neurite elongation (By similarity).
CC       {ECO:0000250|UniProtKB:Q9WUD9}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:14632929, ECO:0000269|PubMed:19307596,
CC         ECO:0000269|PubMed:21036157, ECO:0000269|PubMed:7929427,
CC         ECO:0000269|PubMed:8759729, ECO:0000269|PubMed:9571170};
CC   -!- CATALYTIC ACTIVITY: [Isoform 1]:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000250|UniProtKB:Q9WUD9};
CC   -!- CATALYTIC ACTIVITY: [Isoform 2]:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000250|UniProtKB:Q9WUD9};
CC   -!- CATALYTIC ACTIVITY: [Isoform 3]:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000250|UniProtKB:Q9WUD9};
CC   -!- ACTIVITY REGULATION: Phosphorylation by CSK at Tyr-530 inhibits kinase
CC       activity. Inhibitory phosphorylation at Tyr-530 is enhanced by heme.
CC       Further phosphorylation by CDK1 partially reactivates CSK-inactivated
CC       SRC and facilitates complete reactivation by protein tyrosine
CC       phosphatase PTPRC. Integrin engagement stimulates kinase activity.
CC       Phosphorylation by PTK2/FAK1 enhances kinase activity. Butein and
CC       pseudosubstrate-based peptide inhibitors like CIYKYYF act as
CC       inhibitors. Phosphorylation at Tyr-419 increases kinase activity.
CC       {ECO:0000269|PubMed:14632929, ECO:0000269|PubMed:21036157,
CC       ECO:0000269|PubMed:7929427, ECO:0000269|PubMed:8759729,
CC       ECO:0000269|PubMed:9571170}.
CC   -!- SUBUNIT: Part of a complex comprised of PTPRA, BCAR1, BCAR3 (via SH2
CC       domain) and SRC; the formation of the complex is dependent on integrin
CC       mediated-tyrosine phosphorylation of PTPRA (PubMed:22801373). Interacts
CC       with DDEF1/ASAP1; via the SH3 domain (By similarity). Interacts with
CC       CCPG1 (By similarity). Identified in a complex containing FGFR4, NCAM1,
CC       CDH2, PLCG1, FRS2, SRC, SHC1, GAP43 and CTTN (By similarity). Interacts
CC       with ERBB2, STAT1 and PNN (By similarity). Interacts with DDR1, DDR2
CC       and DAB2 (By similarity). Interacts with CDCP1, TGFB1I1 and TOM1L2
CC       (PubMed:15851033, PubMed:16479011, PubMed:17202804). Interacts with the
CC       cytoplasmic domain of MUC1, phosphorylates it and increases binding of
CC       MUC1 with beta-catenin (PubMed:11152665). Interacts with RALGPS1; via
CC       the SH3 domain (PubMed:10747847). Interacts with CAV2 (tyrosine
CC       phosphorylated form) (PubMed:12091389, PubMed:15504032). Interacts (via
CC       the SH3 domain and the protein kinase domain) with ARRB1; the
CC       interaction is independent of the phosphorylation state of SRC C-
CC       terminus (By similarity). Interacts with ARRB1 and ARRB2
CC       (PubMed:10753943, PubMed:9924018). Interacts with SRCIN1
CC       (PubMed:17525734). Interacts with NDFIP2 and more weakly with NDFIP1
CC       (PubMed:20534535). Interacts with PIK3CA and/or PIK3C2B, PTK2/FAK1 and
CC       ESR1 (dimethylated on arginine) (PubMed:18657504, PubMed:21411625).
CC       Interacts with FASLG (PubMed:19807924). Interacts (via SH2 domain) with
CC       the 'Tyr-402' phosphorylated form of PTK2B/PYK2 (PubMed:14585963).
CC       Interacts (via SH2 domain) with FLT3 (tyrosine phosphorylated) (By
CC       similarity). Interacts with PDGFRA (tyrosine phosphorylated) (By
CC       similarity). Interacts with CSF1R (By similarity). Interacts (via SH2
CC       and SH3 domain) with TNK2 (PubMed:21309750). Interacts (via protein
CC       kinase domain) with the tyrosine phosphorylated form of RUNX3 (via runt
CC       domain) (PubMed:20100835). Interacts with TRAF3 (via RING-type zinc
CC       finger domain) (PubMed:19419966). Interacts with DDX58, MAVS and TBK1
CC       (PubMed:19419966). Interacts (via SH2 domain) with RACK1; the
CC       interaction is enhanced by tyrosine phosphorylation of RACK1 and
CC       inhibits SRC activity (PubMed:9584165, PubMed:11279199). Interacts with
CC       EPHB1; activates the MAPK/ERK cascade to regulate cell migration
CC       (PubMed:12925710). Interacts with FCAMR (PubMed:8759729). Interacts
CC       (via SH2 domain) with the 'Tyr-9' phosphorylated form of PDPK1
CC       (PubMed:18024423). Interacts with AMOTL2; this interaction regulates
CC       the translocation of phosphorylated SRC to peripheral cell-matrix
CC       adhesion sites (PubMed:17293535). Interacts with TRAP1
CC       (PubMed:23564345). Interacts with CBLC; the interaction is enhanced
CC       when SRC is phosphorylated at Tyr-419 (PubMed:14661060,
CC       PubMed:22888118). Interacts with ARHGEF5 (By similarity). Interacts
CC       (via cytoplasmic domain) with CEACAM1 (via SH2 domain); this
CC       interaction is regulated by trans-homophilic cell adhesion
CC       (PubMed:7478590). Interacts with MPP2 (PubMed:19665017). Interacts with
CC       PRR7 (PubMed:21460222). Interacts (via kinase domain and to a lesser
CC       extent the SH2 domain) directly with PDLIM4; this interaction results
CC       in PTPN13-mediated dephosphorylation of this protein leading to its
CC       inactivation (PubMed:19307596). Interacts with P85 (PIK3R1 or PIK3R2)
CC       (PubMed:28903391). Interacts with HNRNPA2B1 (PubMed:31320558).
CC       Interacts with IL6ST/gp130 (PubMed:25731159). Interacts (via SH3
CC       domain) with PELP1 in the presence of 17-beta-estradiol. Interacts with
CC       AMBRA1 (By similarity). {ECO:0000250|UniProtKB:P05480,
CC       ECO:0000250|UniProtKB:Q9WUD9, ECO:0000269|PubMed:10747847,
CC       ECO:0000269|PubMed:10753943, ECO:0000269|PubMed:11152665,
CC       ECO:0000269|PubMed:11279199, ECO:0000269|PubMed:12091389,
CC       ECO:0000269|PubMed:12925710, ECO:0000269|PubMed:14585963,
CC       ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:14963108,
CC       ECO:0000269|PubMed:15504032, ECO:0000269|PubMed:15851033,
CC       ECO:0000269|PubMed:16479011, ECO:0000269|PubMed:17202804,
CC       ECO:0000269|PubMed:17293535, ECO:0000269|PubMed:17525734,
CC       ECO:0000269|PubMed:18024423, ECO:0000269|PubMed:18657504,
CC       ECO:0000269|PubMed:19307596, ECO:0000269|PubMed:19419966,
CC       ECO:0000269|PubMed:19665017, ECO:0000269|PubMed:19807924,
CC       ECO:0000269|PubMed:20100835, ECO:0000269|PubMed:20534535,
CC       ECO:0000269|PubMed:21309750, ECO:0000269|PubMed:21411625,
CC       ECO:0000269|PubMed:22801373, ECO:0000269|PubMed:22888118,
CC       ECO:0000269|PubMed:23564345, ECO:0000269|PubMed:25731159,
CC       ECO:0000269|PubMed:28903391, ECO:0000269|PubMed:31320558,
CC       ECO:0000269|PubMed:7478590, ECO:0000269|PubMed:8759729,
CC       ECO:0000269|PubMed:9584165, ECO:0000269|PubMed:9924018}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HEV ORF3 protein; via the
CC       SH3 domain. {ECO:0000269|PubMed:11518702}.
CC   -!- SUBUNIT: (Microbial infection) Interacts (via SH2 domain) with HCV non-
CC       structural protein 5A (via N-terminus). {ECO:0000269|PubMed:30862675}.
CC   -!- INTERACTION:
CC       P12931; P00519: ABL1; NbExp=2; IntAct=EBI-621482, EBI-375543;
CC       P12931; P42684: ABL2; NbExp=2; IntAct=EBI-621482, EBI-1102694;
CC       P12931; P12814: ACTN1; NbExp=2; IntAct=EBI-621482, EBI-351710;
CC       P12931; O14672: ADAM10; NbExp=3; IntAct=EBI-621482, EBI-1536151;
CC       P12931; O43184: ADAM12; NbExp=2; IntAct=EBI-621482, EBI-2625825;
CC       P12931; Q13444: ADAM15; NbExp=4; IntAct=EBI-621482, EBI-77818;
CC       P12931; P07550: ADRB2; NbExp=3; IntAct=EBI-621482, EBI-491169;
CC       P12931; P55196: AFDN; NbExp=7; IntAct=EBI-621482, EBI-365875;
CC       P12931; P10275: AR; NbExp=7; IntAct=EBI-621482, EBI-608057;
CC       P12931; P49407: ARRB1; NbExp=3; IntAct=EBI-621482, EBI-743313;
CC       P12931; P32121: ARRB2; NbExp=2; IntAct=EBI-621482, EBI-714559;
CC       P12931; Q9ULH1: ASAP1; NbExp=3; IntAct=EBI-621482, EBI-346622;
CC       P12931; Q6XD76: ASCL4; NbExp=3; IntAct=EBI-621482, EBI-10254793;
CC       P12931; P56945: BCAR1; NbExp=3; IntAct=EBI-621482, EBI-702093;
CC       P12931; Q14457: BECN1; NbExp=3; IntAct=EBI-621482, EBI-949378;
CC       P12931; P22681: CBL; NbExp=8; IntAct=EBI-621482, EBI-518228;
CC       P12931; Q16543: CDC37; NbExp=5; IntAct=EBI-621482, EBI-295634;
CC       P12931; Q9H5V8: CDCP1; NbExp=3; IntAct=EBI-621482, EBI-1019736;
CC       P12931; P12830: CDH1; NbExp=2; IntAct=EBI-621482, EBI-727477;
CC       P12931; P68400: CSNK2A1; NbExp=2; IntAct=EBI-621482, EBI-347804;
CC       P12931; P35222: CTNNB1; NbExp=2; IntAct=EBI-621482, EBI-491549;
CC       P12931; P00533: EGFR; NbExp=9; IntAct=EBI-621482, EBI-297353;
CC       P12931; P04626: ERBB2; NbExp=11; IntAct=EBI-621482, EBI-641062;
CC       P12931; P21860: ERBB3; NbExp=2; IntAct=EBI-621482, EBI-720706;
CC       P12931; P03372: ESR1; NbExp=12; IntAct=EBI-621482, EBI-78473;
CC       P12931; P03372-4: ESR1; NbExp=2; IntAct=EBI-621482, EBI-4309277;
CC       P12931; P14921-1: ETS1; NbExp=2; IntAct=EBI-621482, EBI-913224;
CC       P12931; P25445: FAS; NbExp=2; IntAct=EBI-621482, EBI-494743;
CC       P12931; Q8NFZ0: FBH1; NbExp=4; IntAct=EBI-621482, EBI-724767;
CC       P12931; P06241: FYN; NbExp=3; IntAct=EBI-621482, EBI-515315;
CC       P12931; Q13480: GAB1; NbExp=12; IntAct=EBI-621482, EBI-517684;
CC       P12931; Q13322-4: GRB10; NbExp=3; IntAct=EBI-621482, EBI-12353035;
CC       P12931; P19367: HK1; NbExp=2; IntAct=EBI-621482, EBI-713162;
CC       P12931; P61978: HNRNPK; NbExp=6; IntAct=EBI-621482, EBI-304185;
CC       P12931; P07900: HSP90AA1; NbExp=3; IntAct=EBI-621482, EBI-296047;
CC       P12931; Q9Y6K9: IKBKG; NbExp=3; IntAct=EBI-621482, EBI-81279;
CC       P12931; P35968: KDR; NbExp=6; IntAct=EBI-621482, EBI-1005487;
CC       P12931; Q07666: KHDRBS1; NbExp=3; IntAct=EBI-621482, EBI-1364;
CC       P12931; P10721: KIT; NbExp=5; IntAct=EBI-621482, EBI-1379503;
CC       P12931; Q9UIH9: KLF15; NbExp=3; IntAct=EBI-621482, EBI-2796400;
CC       P12931; Q8TBB1: LNX1; NbExp=6; IntAct=EBI-621482, EBI-739832;
CC       P12931; Q14693: LPIN1; NbExp=3; IntAct=EBI-621482, EBI-5278370;
CC       P12931; P07948: LYN; NbExp=4; IntAct=EBI-621482, EBI-79452;
CC       P12931; Q9H204: MED28; NbExp=3; IntAct=EBI-621482, EBI-514199;
CC       P12931; P08581: MET; NbExp=4; IntAct=EBI-621482, EBI-1039152;
CC       P12931; Q13177: PAK2; NbExp=2; IntAct=EBI-621482, EBI-1045887;
CC       P12931; P16284: PECAM1; NbExp=3; IntAct=EBI-621482, EBI-716404;
CC       P12931; P27986: PIK3R1; NbExp=7; IntAct=EBI-621482, EBI-79464;
CC       P12931; P27986-2: PIK3R1; NbExp=3; IntAct=EBI-621482, EBI-9090282;
CC       P12931; Q92569: PIK3R3; NbExp=3; IntAct=EBI-621482, EBI-79893;
CC       P12931; Q05397: PTK2; NbExp=9; IntAct=EBI-621482, EBI-702142;
CC       P12931; Q14289: PTK2B; NbExp=3; IntAct=EBI-621482, EBI-298640;
CC       P12931; P18031: PTPN1; NbExp=14; IntAct=EBI-621482, EBI-968788;
CC       P12931; Q16825: PTPN21; NbExp=2; IntAct=EBI-621482, EBI-2860264;
CC       P12931; P18433: PTPRA; NbExp=4; IntAct=EBI-621482, EBI-2609645;
CC       P12931; Q15907: RAB11B; NbExp=3; IntAct=EBI-621482, EBI-722234;
CC       P12931; Q13905: RAPGEF1; NbExp=2; IntAct=EBI-621482, EBI-976876;
CC       P12931; Q01973: ROR1; NbExp=9; IntAct=EBI-621482, EBI-6082337;
CC       P12931; P27635: RPL10; NbExp=6; IntAct=EBI-621482, EBI-352398;
CC       P12931; O00560: SDCBP; NbExp=2; IntAct=EBI-621482, EBI-727004;
CC       P12931; O60880: SH2D1A; NbExp=3; IntAct=EBI-621482, EBI-6983382;
CC       P12931; O14796: SH2D1B; NbExp=3; IntAct=EBI-621482, EBI-3923013;
CC       P12931; P35326: SPRR2A; NbExp=3; IntAct=EBI-621482, EBI-1047940;
CC       P12931; Q9C0H9: SRCIN1; NbExp=3; IntAct=EBI-621482, EBI-1393949;
CC       P12931; Q13829: TNFAIP1; NbExp=3; IntAct=EBI-621482, EBI-2505861;
CC       P12931; Q68CZ2: TNS3; NbExp=13; IntAct=EBI-621482, EBI-1220488;
CC       P12931; Q9UNY5: ZNF232; NbExp=3; IntAct=EBI-621482, EBI-749023;
CC       P12931; Q8R5G7: Arap3; Xeno; NbExp=3; IntAct=EBI-621482, EBI-621463;
CC       P12931; P52800: Efnb2; Xeno; NbExp=2; IntAct=EBI-621482, EBI-1032676;
CC       P12931; P97288: Htr4; Xeno; NbExp=2; IntAct=EBI-621482, EBI-7149283;
CC       P12931; P34152: Ptk2; Xeno; NbExp=2; IntAct=EBI-621482, EBI-77070;
CC       P12931; P18052: Ptpra; Xeno; NbExp=3; IntAct=EBI-621482, EBI-6597520;
CC       P12931; Q62884; Xeno; NbExp=3; IntAct=EBI-621482, EBI-7459400;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:7525268};
CC       Lipid-anchor {ECO:0000269|PubMed:22801373}. Mitochondrion inner
CC       membrane {ECO:0000269|PubMed:12615910}. Nucleus
CC       {ECO:0000269|PubMed:7853507}. Cytoplasm, cytoskeleton
CC       {ECO:0000269|PubMed:7525268}. Cytoplasm, perinuclear region
CC       {ECO:0000269|PubMed:19307596}. Cell junction, focal adhesion
CC       {ECO:0000269|PubMed:22801373}. Note=Localizes to focal adhesion sites
CC       following integrin engagement (PubMed:22801373). Localization to focal
CC       adhesion sites requires myristoylation and the SH3 domain
CC       (PubMed:7525268). Colocalizes with PDLIM4 at the perinuclear region,
CC       but not at focal adhesions (PubMed:19307596).
CC       {ECO:0000269|PubMed:19307596, ECO:0000269|PubMed:22801373,
CC       ECO:0000269|PubMed:7525268}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=c-src {ECO:0000303|PubMed:8319227};
CC         IsoId=P12931-1; Sequence=Displayed;
CC       Name=2; Synonyms=c-srcN1 {ECO:0000303|PubMed:8319227}, N1-Src
CC       {ECO:0000250|UniProtKB:Q9WUD9};
CC         IsoId=P12931-2; Sequence=VSP_012134;
CC       Name=3; Synonyms=c-srcN2 {ECO:0000303|PubMed:8319227}, N2-Src
CC       {ECO:0000250|UniProtKB:Q9WUD9};
CC         IsoId=P12931-3; Sequence=VSP_061494;
CC   -!- TISSUE SPECIFICITY: Expressed ubiquitously. Platelets, neurons and
CC       osteoclasts express 5-fold to 200-fold higher levels than most other
CC       tissues.
CC   -!- TISSUE SPECIFICITY: [Isoform 1]: Expressed in spleen and liver.
CC       {ECO:0000269|PubMed:8319227}.
CC   -!- TISSUE SPECIFICITY: [Isoform 2]: Expressed in brain.
CC       {ECO:0000269|PubMed:8319227}.
CC   -!- TISSUE SPECIFICITY: [Isoform 3]: Expressed in brain.
CC       {ECO:0000269|PubMed:8319227}.
CC   -!- DEVELOPMENTAL STAGE: [Isoform 1]: Expressed at higher levels in fetal
CC       liver than in adult liver. {ECO:0000269|PubMed:1691439}.
CC   -!- DEVELOPMENTAL STAGE: [Isoform 2]: Expressed at higher levels in fetal
CC       brain than in adult brain. {ECO:0000269|PubMed:1691439}.
CC   -!- DEVELOPMENTAL STAGE: [Isoform 3]: Expressed at similar levels in adult
CC       and fetal brain. {ECO:0000269|PubMed:1691439}.
CC   -!- DOMAIN: The SH2 and SH3 domains are important for the intramolecular
CC       and intermolecular interactions that regulate catalytic activity,
CC       localization, and substrate recruitment.
CC   -!- PTM: Myristoylated at Gly-2, and this is essential for targeting to
CC       membranes. {ECO:0000269|PubMed:7525268}.
CC   -!- PTM: Dephosphorylated at Tyr-530 by PTPRJ (By similarity).
CC       Phosphorylated on Tyr-530 by c-Src kinase (CSK). The phosphorylated
CC       form is termed pp60c-src. Dephosphorylated by PTPRJ at Tyr-419.
CC       Normally maintained in an inactive conformation with the SH2 domain
CC       engaged with Tyr-530, the SH3 domain engaged with the SH2-kinase
CC       linker, and Tyr-419 dephosphorylated. Dephosphorylation of Tyr-530 as a
CC       result of protein tyrosine phosphatase (PTP) action disrupts the
CC       intramolecular interaction between the SH2 domain and Tyr-530, Tyr-419
CC       can then become autophosphorylated, resulting in SRC activation.
CC       Phosphorylation of Tyr-530 by CSK allows this interaction to reform,
CC       resulting in SRC inactivation. CDK5-mediated phosphorylation at Ser-75
CC       targets SRC to ubiquitin-dependent degradation and thus leads to
CC       cytoskeletal reorganization. Phosphorylated by PTK2/FAK1; this enhances
CC       kinase activity. Phosphorylated by PTK2B/PYK2; this enhances kinase
CC       activity. Upon activation of IL6ST by IL6, Tyr-419 is phosphorylated
CC       and Tyr-530 dephosphorylated (PubMed:25731159). {ECO:0000250,
CC       ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:18936167,
CC       ECO:0000269|PubMed:21442427, ECO:0000269|PubMed:22888118,
CC       ECO:0000269|PubMed:25731159, ECO:0000269|PubMed:6273838,
CC       ECO:0000269|PubMed:7525268}.
CC   -!- PTM: [Isoform 1]: Displays reduced levels of autophosphorylation at
CC       Tyr-419 compared to isoforms 2 and 3. {ECO:0000250|UniProtKB:Q9WUD9}.
CC   -!- PTM: [Isoform 2]: Displays enhanced levels of autophosphorylation at
CC       Tyr-419 compared to isoform 1. {ECO:0000250|UniProtKB:Q9WUD9}.
CC   -!- PTM: [Isoform 3]: Displays enhanced levels of autophosphorylation at
CC       Tyr-419 compared to isoform 1 (By similarity). Shows reduced
CC       phosphorylation at Tyr-527 compared to isoforms 1 and 2 (By
CC       similarity). {ECO:0000250|UniProtKB:Q9WUD9}.
CC   -!- PTM: S-nitrosylation is important for activation of its kinase
CC       activity. {ECO:0000250}.
CC   -!- PTM: Ubiquitinated in response to CDK5-mediated phosphorylation.
CC       Ubiquitination mediated by CBLC requires SRC autophosphorylation at
CC       Tyr-419 and may lead to lysosomal degradation.
CC       {ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:18936167,
CC       ECO:0000269|PubMed:22888118, ECO:0000269|PubMed:6273838}.
CC   -!- DISEASE: Note=SRC kinase activity has been shown to be increased in
CC       several tumor tissues and tumor cell lines such as colon carcinoma
CC       cells. {ECO:0000269|PubMed:2498394, ECO:0000269|PubMed:3093483}.
CC   -!- DISEASE: Thrombocytopenia 6 (THC6) [MIM:616937]: A form of
CC       thrombocytopenia, a hematologic disorder defined by a decrease in the
CC       number of platelets in circulating blood, resulting in the potential
CC       for increased bleeding and decreased ability for clotting. THC6 is an
CC       autosomal dominant form. Affected individuals may also have bone
CC       abnormalities and an increased risk for myelofibrosis.
CC       {ECO:0000269|PubMed:26936507}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. SRC subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/SRCID448ch20q11.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AL133293; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471077; EAW76065.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW76064.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW76066.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW76067.1; -; Genomic_DNA.
DR   EMBL; BC011566; AAH11566.1; -; mRNA.
DR   EMBL; BC051270; AAH51270.2; -; mRNA.
DR   EMBL; K03218; AAA60584.1; -; Genomic_DNA.
DR   EMBL; M16237; AAA60584.1; JOINED; Genomic_DNA.
DR   EMBL; M16243; AAA60584.1; JOINED; Genomic_DNA.
DR   EMBL; M16244; AAA60584.1; JOINED; Genomic_DNA.
DR   EMBL; M16245; AAA60584.1; JOINED; Genomic_DNA.
DR   EMBL; K03212; AAA60584.1; JOINED; Genomic_DNA.
DR   EMBL; K03213; AAA60584.1; JOINED; Genomic_DNA.
DR   EMBL; K03214; AAA60584.1; JOINED; Genomic_DNA.
DR   EMBL; K03215; AAA60584.1; JOINED; Genomic_DNA.
DR   EMBL; K03216; AAA60584.1; JOINED; Genomic_DNA.
DR   EMBL; K03217; AAA60584.1; JOINED; Genomic_DNA.
DR   EMBL; X02647; CAA26485.1; -; Genomic_DNA.
DR   EMBL; X03995; CAA26485.1; JOINED; Genomic_DNA.
DR   EMBL; X03996; CAA26485.1; JOINED; Genomic_DNA.
DR   EMBL; X03997; CAA26485.1; JOINED; Genomic_DNA.
DR   EMBL; X03998; CAA26485.1; JOINED; Genomic_DNA.
DR   EMBL; X03999; CAA26485.1; JOINED; Genomic_DNA.
DR   EMBL; X04000; CAA26485.1; JOINED; Genomic_DNA.
DR   CCDS; CCDS13294.1; -. [P12931-1]
DR   PIR; A26891; TVHUSC.
DR   RefSeq; NP_005408.1; NM_005417.4. [P12931-1]
DR   RefSeq; NP_938033.1; NM_198291.2. [P12931-1]
DR   RefSeq; XP_011527315.1; XM_011529013.2. [P12931-1]
DR   RefSeq; XP_016883513.1; XM_017028024.1. [P12931-2]
DR   RefSeq; XP_016883514.1; XM_017028025.1. [P12931-2]
DR   RefSeq; XP_016883515.1; XM_017028026.1. [P12931-2]
DR   RefSeq; XP_016883516.1; XM_017028027.1. [P12931-2]
DR   PDB; 1A07; X-ray; 2.20 A; A/B=144-249.
DR   PDB; 1A08; X-ray; 2.20 A; A/B=144-249.
DR   PDB; 1A09; X-ray; 2.00 A; A/B=144-249.
DR   PDB; 1A1A; X-ray; 2.00 A; A/B=144-249.
DR   PDB; 1A1B; X-ray; 2.20 A; A/B=144-249.
DR   PDB; 1A1C; X-ray; 2.40 A; A/B=144-249.
DR   PDB; 1A1E; X-ray; 2.20 A; A/B=144-249.
DR   PDB; 1FMK; X-ray; 1.50 A; A=86-536.
DR   PDB; 1HCS; NMR; -; B=144-249.
DR   PDB; 1HCT; NMR; -; B=144-249.
DR   PDB; 1KSW; X-ray; 2.80 A; A=86-536.
DR   PDB; 1O41; X-ray; 1.70 A; A=145-252.
DR   PDB; 1O42; X-ray; 1.70 A; A=145-252.
DR   PDB; 1O43; X-ray; 1.50 A; A=145-252.
DR   PDB; 1O44; X-ray; 1.70 A; A=145-252.
DR   PDB; 1O45; X-ray; 1.80 A; A=145-252.
DR   PDB; 1O46; X-ray; 2.00 A; A=145-252.
DR   PDB; 1O47; X-ray; 1.80 A; A=145-252.
DR   PDB; 1O48; X-ray; 1.55 A; A=145-252.
DR   PDB; 1O49; X-ray; 1.70 A; A=145-252.
DR   PDB; 1O4A; X-ray; 1.50 A; A=145-252.
DR   PDB; 1O4B; X-ray; 1.85 A; A=145-252.
DR   PDB; 1O4C; X-ray; 1.80 A; A=145-252.
DR   PDB; 1O4D; X-ray; 1.85 A; A=145-252.
DR   PDB; 1O4E; X-ray; 2.00 A; A=145-252.
DR   PDB; 1O4F; X-ray; 2.00 A; A=145-252.
DR   PDB; 1O4G; X-ray; 1.55 A; A=145-252.
DR   PDB; 1O4H; X-ray; 2.25 A; A=145-252.
DR   PDB; 1O4I; X-ray; 1.75 A; A=145-252.
DR   PDB; 1O4J; X-ray; 1.70 A; A=145-252.
DR   PDB; 1O4K; X-ray; 1.57 A; A=145-252.
DR   PDB; 1O4L; X-ray; 1.65 A; A=145-252.
DR   PDB; 1O4M; X-ray; 1.60 A; A=145-252.
DR   PDB; 1O4N; X-ray; 1.60 A; A=145-252.
DR   PDB; 1O4O; X-ray; 1.70 A; A=145-252.
DR   PDB; 1O4P; X-ray; 1.90 A; A=145-252.
DR   PDB; 1O4Q; X-ray; 1.70 A; A=145-252.
DR   PDB; 1O4R; X-ray; 1.50 A; A=145-252.
DR   PDB; 1SHD; X-ray; 2.00 A; A=144-249.
DR   PDB; 1Y57; X-ray; 1.91 A; A=86-536.
DR   PDB; 1YI6; X-ray; 2.00 A; A/B=261-536.
DR   PDB; 1YOJ; X-ray; 1.95 A; A/B=254-536.
DR   PDB; 1YOL; X-ray; 2.30 A; A/B=254-536.
DR   PDB; 1YOM; X-ray; 2.90 A; A/B=254-536.
DR   PDB; 2BDF; X-ray; 2.10 A; A/B=258-536.
DR   PDB; 2BDJ; X-ray; 2.50 A; A=258-536.
DR   PDB; 2H8H; X-ray; 2.20 A; A=2-536.
DR   PDB; 2SRC; X-ray; 1.50 A; A=86-536.
DR   PDB; 3VRO; X-ray; 1.80 A; B=412-424.
DR   PDB; 3ZMP; X-ray; 2.62 A; C/D=527-536.
DR   PDB; 3ZMQ; X-ray; 3.30 A; C=527-536.
DR   PDB; 4F59; X-ray; 1.71 A; A=144-252.
DR   PDB; 4F5A; X-ray; 1.80 A; A=144-252.
DR   PDB; 4F5B; X-ray; 1.57 A; A=144-252.
DR   PDB; 4HXJ; X-ray; 2.00 A; A/B=87-144.
DR   PDB; 4K11; X-ray; 2.30 A; A=87-534.
DR   PDB; 4MXO; X-ray; 2.10 A; A/B=254-536.
DR   PDB; 4MXX; X-ray; 2.60 A; A/B=254-536.
DR   PDB; 4MXY; X-ray; 2.58 A; A/B=254-536.
DR   PDB; 4MXZ; X-ray; 2.58 A; A/B=254-536.
DR   PDB; 6ATE; X-ray; 2.40 A; A=254-536.
DR   PDB; 6C4S; X-ray; 1.50 A; A/B=87-144.
DR   PDB; 6E6E; X-ray; 2.15 A; A/B/C/D/E/F/G/H=261-536.
DR   PDB; 6EHJ; X-ray; 2.10 A; D/F=2-9.
DR   PDB; 7NG7; X-ray; 1.50 A; A=254-536.
DR   PDBsum; 1A07; -.
DR   PDBsum; 1A08; -.
DR   PDBsum; 1A09; -.
DR   PDBsum; 1A1A; -.
DR   PDBsum; 1A1B; -.
DR   PDBsum; 1A1C; -.
DR   PDBsum; 1A1E; -.
DR   PDBsum; 1FMK; -.
DR   PDBsum; 1HCS; -.
DR   PDBsum; 1HCT; -.
DR   PDBsum; 1KSW; -.
DR   PDBsum; 1O41; -.
DR   PDBsum; 1O42; -.
DR   PDBsum; 1O43; -.
DR   PDBsum; 1O44; -.
DR   PDBsum; 1O45; -.
DR   PDBsum; 1O46; -.
DR   PDBsum; 1O47; -.
DR   PDBsum; 1O48; -.
DR   PDBsum; 1O49; -.
DR   PDBsum; 1O4A; -.
DR   PDBsum; 1O4B; -.
DR   PDBsum; 1O4C; -.
DR   PDBsum; 1O4D; -.
DR   PDBsum; 1O4E; -.
DR   PDBsum; 1O4F; -.
DR   PDBsum; 1O4G; -.
DR   PDBsum; 1O4H; -.
DR   PDBsum; 1O4I; -.
DR   PDBsum; 1O4J; -.
DR   PDBsum; 1O4K; -.
DR   PDBsum; 1O4L; -.
DR   PDBsum; 1O4M; -.
DR   PDBsum; 1O4N; -.
DR   PDBsum; 1O4O; -.
DR   PDBsum; 1O4P; -.
DR   PDBsum; 1O4Q; -.
DR   PDBsum; 1O4R; -.
DR   PDBsum; 1SHD; -.
DR   PDBsum; 1Y57; -.
DR   PDBsum; 1YI6; -.
DR   PDBsum; 1YOJ; -.
DR   PDBsum; 1YOL; -.
DR   PDBsum; 1YOM; -.
DR   PDBsum; 2BDF; -.
DR   PDBsum; 2BDJ; -.
DR   PDBsum; 2H8H; -.
DR   PDBsum; 2SRC; -.
DR   PDBsum; 3VRO; -.
DR   PDBsum; 3ZMP; -.
DR   PDBsum; 3ZMQ; -.
DR   PDBsum; 4F59; -.
DR   PDBsum; 4F5A; -.
DR   PDBsum; 4F5B; -.
DR   PDBsum; 4HXJ; -.
DR   PDBsum; 4K11; -.
DR   PDBsum; 4MXO; -.
DR   PDBsum; 4MXX; -.
DR   PDBsum; 4MXY; -.
DR   PDBsum; 4MXZ; -.
DR   PDBsum; 6ATE; -.
DR   PDBsum; 6C4S; -.
DR   PDBsum; 6E6E; -.
DR   PDBsum; 6EHJ; -.
DR   PDBsum; 7NG7; -.
DR   AlphaFoldDB; P12931; -.
DR   BMRB; P12931; -.
DR   SASBDB; P12931; -.
DR   SMR; P12931; -.
DR   BioGRID; 112592; 547.
DR   CORUM; P12931; -.
DR   DIP; DIP-1059N; -.
DR   ELM; P12931; -.
DR   IntAct; P12931; 388.
DR   MINT; P12931; -.
DR   STRING; 9606.ENSP00000362680; -.
DR   BindingDB; P12931; -.
DR   ChEMBL; CHEMBL267; -.
DR   DrugBank; DB08564; (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide.
DR   DrugBank; DB08054; 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine.
DR   DrugBank; DB06882; 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea.
DR   DrugBank; DB06883; 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea.
DR   DrugBank; DB08053; 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine.
DR   DrugBank; DB03023; 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine.
DR   DrugBank; DB08192; 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE.
DR   DrugBank; DB03104; 2-[4-[(Z)-2-Acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]prop-1-enyl]-2-formylphenyl]acetic acid.
DR   DrugBank; DB07335; 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL.
DR   DrugBank; DB04739; 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE.
DR   DrugBank; DB07966; [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile.
DR   DrugBank; DB06616; Bosutinib.
DR   DrugBank; DB04272; Citric acid.
DR   DrugBank; DB01254; Dasatinib.
DR   DrugBank; DB03217; DPI59.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB03628; ISO24.
DR   DrugBank; DB02175; Malonic acid.
DR   DrugBank; DB08462; N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE.
DR   DrugBank; DB01893; N6-Benzyl Adenosine-5'-Diphosphate.
DR   DrugBank; DB09079; Nintedanib.
DR   DrugBank; DB03902; Oxalic Acid.
DR   DrugBank; DB04495; Paratoulene phosphate.
DR   DrugBank; DB03114; PAS219.
DR   DrugBank; DB03078; PASBN.
DR   DrugBank; DB07662; PD-168393.
DR   DrugBank; DB03298; Phenylphosphate.
DR   DrugBank; DB01962; Phosphonotyrosine.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB08052; PP-121.
DR   DrugBank; DB04751; Purvalanol A.
DR   DrugBank; DB04080; RU78191.
DR   DrugBank; DB01947; RU78262.
DR   DrugBank; DB03828; RU78299.
DR   DrugBank; DB03306; RU78300.
DR   DrugBank; DB02908; RU78783.
DR   DrugBank; DB02762; RU79072.
DR   DrugBank; DB03525; RU79073.
DR   DrugBank; DB01866; RU79256.
DR   DrugBank; DB03268; RU82197.
DR   DrugBank; DB03591; RU82209.
DR   DrugBank; DB02336; RU83876.
DR   DrugBank; DB01678; RU84687.
DR   DrugBank; DB03712; RU85053.
DR   DrugBank; DB01908; RU85493.
DR   DrugBank; DB02432; RU90395.
DR   DrugBank; DB06137; Tirbanibulin.
DR   DrugBank; DB05184; XL228.
DR   DrugCentral; P12931; -.
DR   GuidetoPHARMACOLOGY; 2206; -.
DR   MoonDB; P12931; Predicted.
DR   TCDB; 8.A.23.1.12; the basigin (basigin) family.
DR   GlyGen; P12931; 2 sites, 1 O-linked glycan (1 site).
DR   iPTMnet; P12931; -.
DR   PhosphoSitePlus; P12931; -.
DR   SwissPalm; P12931; -.
DR   BioMuta; SRC; -.
DR   DMDM; 125711; -.
DR   OGP; P12931; -.
DR   CPTAC; CPTAC-905; -.
DR   EPD; P12931; -.
DR   jPOST; P12931; -.
DR   MassIVE; P12931; -.
DR   MaxQB; P12931; -.
DR   PaxDb; P12931; -.
DR   PeptideAtlas; P12931; -.
DR   PRIDE; P12931; -.
DR   ProteomicsDB; 52884; -. [P12931-1]
DR   ProteomicsDB; 52885; -. [P12931-2]
DR   ABCD; P12931; 8 sequenced antibodies.
DR   Antibodypedia; 3409; 1986 antibodies from 46 providers.
DR   DNASU; 6714; -.
DR   Ensembl; ENST00000358208.9; ENSP00000350941.5; ENSG00000197122.13. [P12931-3]
DR   Ensembl; ENST00000373558.2; ENSP00000362659.2; ENSG00000197122.13. [P12931-2]
DR   Ensembl; ENST00000373567.6; ENSP00000362668.2; ENSG00000197122.13. [P12931-1]
DR   Ensembl; ENST00000373578.7; ENSP00000362680.2; ENSG00000197122.13. [P12931-1]
DR   Ensembl; ENST00000692112.1; ENSP00000508666.1; ENSG00000197122.13. [P12931-1]
DR   Ensembl; ENST00000692423.1; ENSP00000509325.1; ENSG00000197122.13. [P12931-1]
DR   GeneID; 6714; -.
DR   KEGG; hsa:6714; -.
DR   MANE-Select; ENST00000373578.7; ENSP00000362680.2; NM_198291.3; NP_938033.1.
DR   UCSC; uc002xgy.5; human. [P12931-1]
DR   CTD; 6714; -.
DR   DisGeNET; 6714; -.
DR   GeneCards; SRC; -.
DR   HGNC; HGNC:11283; SRC.
DR   HPA; ENSG00000197122; Low tissue specificity.
DR   MalaCards; SRC; -.
DR   MIM; 190090; gene.
DR   MIM; 616937; phenotype.
DR   neXtProt; NX_P12931; -.
DR   OpenTargets; ENSG00000197122; -.
DR   Orphanet; 480851; Hereditary thrombocytopenia with early-onset myelofibrosis.
DR   PharmGKB; PA36111; -.
DR   VEuPathDB; HostDB:ENSG00000197122; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   GeneTree; ENSGT00940000158250; -.
DR   HOGENOM; CLU_000288_7_2_1; -.
DR   InParanoid; P12931; -.
DR   OMA; GMMNMEV; -.
DR   OrthoDB; 1155741at2759; -.
DR   PhylomeDB; P12931; -.
DR   TreeFam; TF351634; -.
DR   BioCyc; MetaCyc:HS02256-MON; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   PathwayCommons; P12931; -.
DR   Reactome; R-HSA-1227986; Signaling by ERBB2.
DR   Reactome; R-HSA-1251985; Nuclear signaling by ERBB4.
DR   Reactome; R-HSA-1253288; Downregulation of ERBB4 signaling.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1295596; Spry regulation of FGF signaling. [P12931-1]
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT. [P12931-1]
DR   Reactome; R-HSA-1433559; Regulation of KIT signaling. [P12931-1]
DR   Reactome; R-HSA-171007; p38MAPK events. [P12931-1]
DR   Reactome; R-HSA-177929; Signaling by EGFR. [P12931-1]
DR   Reactome; R-HSA-180292; GAB1 signalosome.
DR   Reactome; R-HSA-186763; Downstream signal transduction.
DR   Reactome; R-HSA-191650; Regulation of gap junction activity. [P12931-2]
DR   Reactome; R-HSA-201556; Signaling by ALK. [P12931-1]
DR   Reactome; R-HSA-2029481; FCGR activation. [P12931-1]
DR   Reactome; R-HSA-210990; PECAM1 interactions. [P12931-1]
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-2682334; EPH-Ephrin signaling. [P12931-1]
DR   Reactome; R-HSA-354192; Integrin signaling.
DR   Reactome; R-HSA-354194; GRB2:SOS provides linkage to MAPK signaling for Integrins.
DR   Reactome; R-HSA-372708; p130Cas linkage to MAPK signaling for integrins.
DR   Reactome; R-HSA-375165; NCAM signaling for neurite out-growth. [P12931-1]
DR   Reactome; R-HSA-389356; CD28 co-stimulation. [P12931-1]
DR   Reactome; R-HSA-389513; CTLA4 inhibitory signaling. [P12931-1]
DR   Reactome; R-HSA-391160; Signal regulatory protein family interactions. [P12931-1]
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling. [P12931-1]
DR   Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse. [P12931-1]
DR   Reactome; R-HSA-3928664; Ephrin signaling. [P12931-1]
DR   Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells. [P12931-1]
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-418592; ADP signalling through P2Y purinoceptor 1. [P12931-1]
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-418885; DCC mediated attractive signaling.
DR   Reactome; R-HSA-418886; Netrin mediated repulsion signals.
DR   Reactome; R-HSA-428542; Regulation of commissural axon pathfinding by SLIT and ROBO.
DR   Reactome; R-HSA-430116; GP1b-IX-V activation signalling. [P12931-1]
DR   Reactome; R-HSA-437239; Recycling pathway of L1. [P12931-1]
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway. [P12931-1]
DR   Reactome; R-HSA-456926; Thrombin signalling through proteinase activated receptors (PARs). [P12931-1]
DR   Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation. [P12931-1]
DR   Reactome; R-HSA-5607764; CLEC7A (Dectin-1) signaling. [P12931-1]
DR   Reactome; R-HSA-5663220; RHO GTPases Activate Formins. [P12931-1]
DR   Reactome; R-HSA-5673000; RAF activation.
DR   Reactome; R-HSA-5674135; MAP2K and MAPK activation.
DR   Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions.
DR   Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-69231; Cyclin D associated events in G1. [P12931-1]
DR   Reactome; R-HSA-8853659; RET signaling. [P12931-1]
DR   Reactome; R-HSA-8874081; MET activates PTK2 signaling.
DR   Reactome; R-HSA-8876493; InlA-mediated entry of Listeria monocytogenes into host cells.
DR   Reactome; R-HSA-8934593; Regulation of RUNX1 Expression and Activity.
DR   Reactome; R-HSA-8934903; Receptor Mediated Mitophagy. [P12931-1]
DR   Reactome; R-HSA-8940973; RUNX2 regulates osteoblast differentiation.
DR   Reactome; R-HSA-8941858; Regulation of RUNX3 expression and activity.
DR   Reactome; R-HSA-9009391; Extra-nuclear estrogen signaling.
DR   Reactome; R-HSA-9013420; RHOU GTPase cycle.
DR   Reactome; R-HSA-9032500; Activated NTRK2 signals through FYN.
DR   Reactome; R-HSA-9603381; Activated NTRK3 signals through PI3K.
DR   Reactome; R-HSA-9620244; Long-term potentiation.
DR   Reactome; R-HSA-9634597; GPER1 signaling.
DR   Reactome; R-HSA-9649948; Signaling downstream of RAS mutants.
DR   Reactome; R-HSA-9656223; Signaling by RAF1 mutants.
DR   Reactome; R-HSA-9664323; FCGR3A-mediated IL10 synthesis. [P12931-1]
DR   Reactome; R-HSA-9664422; FCGR3A-mediated phagocytosis. [P12931-1]
DR   Reactome; R-HSA-9670439; Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants. [P12931-1]
DR   SignaLink; P12931; -.
DR   SIGNOR; P12931; -.
DR   BioGRID-ORCS; 6714; 31 hits in 1121 CRISPR screens.
DR   ChiTaRS; SRC; human.
DR   EvolutionaryTrace; P12931; -.
DR   GeneWiki; Src_(gene); -.
DR   GenomeRNAi; 6714; -.
DR   Pharos; P12931; Tclin.
DR   PRO; PR:P12931; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   RNAct; P12931; protein.
DR   Bgee; ENSG00000197122; Expressed in body of stomach and 161 other tissues.
DR   Genevisible; P12931; HS.
DR   GO; GO:0005884; C:actin filament; IEA:Ensembl.
DR   GO; GO:0005901; C:caveola; IDA:BHF-UCL.
DR   GO; GO:0030054; C:cell junction; IDA:HPA.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:1902737; C:dendritic filopodium; IEA:Ensembl.
DR   GO; GO:0044294; C:dendritic growth cone; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005925; C:focal adhesion; ISS:UniProtKB.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0005770; C:late endosome; IDA:UniProtKB.
DR   GO; GO:0005764; C:lysosome; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; ISS:ARUK-UCL.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0002102; C:podosome; IEA:Ensembl.
DR   GO; GO:0014069; C:postsynaptic density; IEA:Ensembl.
DR   GO; GO:0099091; C:postsynaptic specialization, intracellular component; IEA:Ensembl.
DR   GO; GO:0032587; C:ruffle membrane; IEA:Ensembl.
DR   GO; GO:0097060; C:synaptic membrane; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0051117; F:ATPase binding; ISS:ARUK-UCL.
DR   GO; GO:0070700; F:BMP receptor binding; IPI:ARUK-UCL.
DR   GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL.
DR   GO; GO:0071253; F:connexin binding; IEA:Ensembl.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0046875; F:ephrin receptor binding; IPI:UniProtKB.
DR   GO; GO:0070851; F:growth factor receptor binding; IPI:UniProtKB.
DR   GO; GO:0020037; F:heme binding; IDA:UniProtKB.
DR   GO; GO:0005158; F:insulin receptor binding; IEA:Ensembl.
DR   GO; GO:0005178; F:integrin binding; IPI:UniProtKB.
DR   GO; GO:0008289; F:lipid binding; EXP:DisProt.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:ARUK-UCL.
DR   GO; GO:0030331; F:nuclear estrogen receptor binding; IEA:Ensembl.
DR   GO; GO:0016004; F:phospholipase activator activity; IDA:ARUK-UCL.
DR   GO; GO:0043274; F:phospholipase binding; IPI:ARUK-UCL.
DR   GO; GO:0051219; F:phosphoprotein binding; IPI:UniProtKB.
DR   GO; GO:0008022; F:protein C-terminus binding; IPI:CAFA.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0005080; F:protein kinase C binding; IEA:Ensembl.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0097110; F:scaffold protein binding; IPI:BHF-UCL.
DR   GO; GO:0042169; F:SH2 domain binding; IPI:UniProtKB.
DR   GO; GO:0005102; F:signaling receptor binding; IPI:UniProtKB.
DR   GO; GO:0044325; F:transmembrane transporter binding; IPI:BHF-UCL.
DR   GO; GO:0032148; P:activation of protein kinase B activity; IEA:Ensembl.
DR   GO; GO:0034332; P:adherens junction organization; IEA:Ensembl.
DR   GO; GO:0086098; P:angiotensin-activated signaling pathway involved in heart process; ISS:BHF-UCL.
DR   GO; GO:0045453; P:bone resorption; ISS:UniProtKB.
DR   GO; GO:0060444; P:branching involved in mammary gland duct morphogenesis; IEA:Ensembl.
DR   GO; GO:0007155; P:cell adhesion; IBA:GO_Central.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0098609; P:cell-cell adhesion; IEA:Ensembl.
DR   GO; GO:0071398; P:cellular response to fatty acid; IEA:Ensembl.
DR   GO; GO:0071498; P:cellular response to fluid shear stress; IEA:Ensembl.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IEA:Ensembl.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IEA:Ensembl.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0071375; P:cellular response to peptide hormone stimulus; ISS:BHF-UCL.
DR   GO; GO:0036120; P:cellular response to platelet-derived growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0071393; P:cellular response to progesterone stimulus; ISS:BHF-UCL.
DR   GO; GO:1990646; P:cellular response to prolactin; IEA:Ensembl.
DR   GO; GO:0071897; P:DNA biosynthetic process; IEA:Ensembl.
DR   GO; GO:0035635; P:entry of bacterium into host cell; TAS:Reactome.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0038128; P:ERBB2 signaling pathway; TAS:Reactome.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0048041; P:focal adhesion assembly; IMP:UniProtKB.
DR   GO; GO:0030900; P:forebrain development; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0070102; P:interleukin-6-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0060576; P:intestinal epithelial cell development; IDA:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:ARUK-UCL.
DR   GO; GO:0007611; P:learning or memory; IEA:Ensembl.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0016236; P:macroautophagy; TAS:Reactome.
DR   GO; GO:0051450; P:myoblast proliferation; IEA:Ensembl.
DR   GO; GO:2000811; P:negative regulation of anoikis; IMP:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IMP:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IEA:Ensembl.
DR   GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0051895; P:negative regulation of focal adhesion assembly; ISS:BHF-UCL.
DR   GO; GO:0002862; P:negative regulation of inflammatory response to antigenic stimulus; TAS:Reactome.
DR   GO; GO:2001243; P:negative regulation of intrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0051902; P:negative regulation of mitochondrial depolarization; IMP:UniProtKB.
DR   GO; GO:0031333; P:negative regulation of protein-containing complex assembly; IMP:UniProtKB.
DR   GO; GO:0051974; P:negative regulation of telomerase activity; IMP:BHF-UCL.
DR   GO; GO:0032211; P:negative regulation of telomere maintenance via telomerase; IMP:BHF-UCL.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0042476; P:odontogenesis; IEA:Ensembl.
DR   GO; GO:0048477; P:oogenesis; IEA:Ensembl.
DR   GO; GO:0036035; P:osteoclast development; IBA:GO_Central.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IEA:Ensembl.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IEA:Ensembl.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0045780; P:positive regulation of bone resorption; IEA:Ensembl.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0045737; P:positive regulation of cyclin-dependent protein serine/threonine kinase activity; IEA:Ensembl.
DR   GO; GO:0001819; P:positive regulation of cytokine production; IEA:Ensembl.
DR   GO; GO:0035306; P:positive regulation of dephosphorylation; IDA:ARUK-UCL.
DR   GO; GO:2000573; P:positive regulation of DNA biosynthetic process; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IEA:Ensembl.
DR   GO; GO:0010634; P:positive regulation of epithelial cell migration; IMP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:0010907; P:positive regulation of glucose metabolic process; IEA:Ensembl.
DR   GO; GO:0035332; P:positive regulation of hippo signaling; IMP:FlyBase.
DR   GO; GO:0046628; P:positive regulation of insulin receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0033625; P:positive regulation of integrin activation; TAS:BHF-UCL.
DR   GO; GO:2000394; P:positive regulation of lamellipodium morphogenesis; IMP:UniProtKB.
DR   GO; GO:2000256; P:positive regulation of male germ cell proliferation; IEA:Ensembl.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IEA:Ensembl.
DR   GO; GO:1903997; P:positive regulation of non-membrane spanning protein tyrosine kinase activity; NAS:ARUK-UCL.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; IDA:UniProtKB.
DR   GO; GO:2000386; P:positive regulation of ovarian follicle development; IEA:Ensembl.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IMP:ARUK-UCL.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; IEA:Ensembl.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; TAS:Reactome.
DR   GO; GO:2000588; P:positive regulation of platelet-derived growth factor receptor-beta signaling pathway; IEA:Ensembl.
DR   GO; GO:0071803; P:positive regulation of podosome assembly; IEA:Ensembl.
DR   GO; GO:0031954; P:positive regulation of protein autophosphorylation; IEA:Ensembl.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IMP:UniProtKB.
DR   GO; GO:1900182; P:positive regulation of protein localization to nucleus; IEA:Ensembl.
DR   GO; GO:0010954; P:positive regulation of protein processing; IEA:Ensembl.
DR   GO; GO:0071902; P:positive regulation of protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0051222; P:positive regulation of protein transport; IEA:Ensembl.
DR   GO; GO:0046579; P:positive regulation of Ras protein signal transduction; IEA:Ensembl.
DR   GO; GO:0051057; P:positive regulation of small GTPase mediated signal transduction; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0014911; P:positive regulation of smooth muscle cell migration; IEA:Ensembl.
DR   GO; GO:1904707; P:positive regulation of vascular associated smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0001545; P:primary ovarian follicle growth; IEA:Ensembl.
DR   GO; GO:0050847; P:progesterone receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0031648; P:protein destabilization; IEA:Ensembl.
DR   GO; GO:0045124; P:regulation of bone resorption; TAS:BHF-UCL.
DR   GO; GO:2001286; P:regulation of caveolin-mediated endocytosis; IMP:UniProtKB.
DR   GO; GO:0060491; P:regulation of cell projection assembly; IEA:Ensembl.
DR   GO; GO:0022407; P:regulation of cell-cell adhesion; IMP:UniProtKB.
DR   GO; GO:2000641; P:regulation of early endosome to late endosome transport; IMP:UniProtKB.
DR   GO; GO:0010632; P:regulation of epithelial cell migration; IMP:UniProtKB.
DR   GO; GO:0033146; P:regulation of intracellular estrogen receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0098962; P:regulation of postsynaptic neurotransmitter receptor activity; IEA:Ensembl.
DR   GO; GO:0043393; P:regulation of protein binding; IEA:Ensembl.
DR   GO; GO:0043114; P:regulation of vascular permeability; TAS:BHF-UCL.
DR   GO; GO:0010447; P:response to acidic pH; IEA:Ensembl.
DR   GO; GO:0051602; P:response to electrical stimulus; IEA:Ensembl.
DR   GO; GO:0070555; P:response to interleukin-1; IMP:BHF-UCL.
DR   GO; GO:0009612; P:response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0051385; P:response to mineralocorticoid; IEA:Ensembl.
DR   GO; GO:0031667; P:response to nutrient levels; IEA:Ensembl.
DR   GO; GO:0009615; P:response to virus; IEA:Ensembl.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl.
DR   GO; GO:0007172; P:signal complex assembly; TAS:ProtInc.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0014856; P:skeletal muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0002223; P:stimulatory C-type lectin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0043149; P:stress fiber assembly; IMP:UniProtKB.
DR   GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IEA:Ensembl.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0045056; P:transcytosis; IEA:Ensembl.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   GO; GO:0060065; P:uterus development; IEA:Ensembl.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   DisProt; DP01570; -.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell adhesion; Cell cycle;
KW   Cell junction; Cell membrane; Cytoplasm; Cytoskeleton; Disease variant;
KW   Host-virus interaction; Immunity; Kinase; Lipoprotein; Membrane;
KW   Mitochondrion; Mitochondrion inner membrane; Myristate; Nucleotide-binding;
KW   Nucleus; Phosphoprotein; Proto-oncogene; Reference proteome; SH2 domain;
KW   SH3 domain; Transferase; Tyrosine-protein kinase; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT   CHAIN           2..536
FT                   /note="Proto-oncogene tyrosine-protein kinase Src"
FT                   /id="PRO_0000088141"
FT   DOMAIN          84..145
FT                   /note="SH3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   DOMAIN          151..248
FT                   /note="SH2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   DOMAIN          270..523
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..53
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        389
FT                   /note="Proton acceptor"
FT   BINDING         276..284
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         298
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   MOD_RES         17
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18088087,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         75
FT                   /note="Phosphoserine; by CDK5"
FT                   /evidence="ECO:0000269|PubMed:21442427,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         187
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P05480"
FT   MOD_RES         419
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:14661060,
FT                   ECO:0000269|PubMed:18936167, ECO:0000269|PubMed:19307596,
FT                   ECO:0000269|PubMed:25731159, ECO:0000269|PubMed:26936507,
FT                   ECO:0000269|PubMed:6273838"
FT   MOD_RES         419
FT                   /note="Phosphotyrosine; by FAK2"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         530
FT                   /note="Phosphotyrosine; by CSK"
FT                   /evidence="ECO:0000269|PubMed:19307596,
FT                   ECO:0000269|PubMed:26936507, ECO:0000269|PubMed:7525268,
FT                   ECO:0000269|PubMed:7929427, ECO:0007744|PubMed:19369195"
FT   LIPID           2
FT                   /note="N-myristoyl glycine"
FT                   /evidence="ECO:0000269|PubMed:7525268"
FT   VAR_SEQ         117
FT                   /note="T -> TRKVDVR (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:2681803"
FT                   /id="VSP_012134"
FT   VAR_SEQ         117
FT                   /note="T -> TRKVDVSQTWFTFRWLQR (in isoform 3)"
FT                   /id="VSP_061494"
FT   VARIANT         176
FT                   /note="L -> F (in dbSNP:rs6018260)"
FT                   /id="VAR_051699"
FT   VARIANT         237
FT                   /note="A -> T (in dbSNP:rs34881773)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041830"
FT   VARIANT         527
FT                   /note="E -> K (in THC6; increased protein tyrosine kinase
FT                   activity; increased autophosphorylation at Y-419; causes
FT                   defective megakaryopoiesis associated with increased
FT                   overall tyrosine phosphorylation in megakaryocytes;
FT                   dbSNP:rs879255268)"
FT                   /evidence="ECO:0000269|PubMed:26936507"
FT                   /id="VAR_076919"
FT   MUTAGEN         298
FT                   /note="K->M: Kinase inactive. Abolishes ubiquitination
FT                   promoted by CBLC."
FT                   /evidence="ECO:0000269|PubMed:14661060"
FT   MUTAGEN         302
FT                   /note="P->E: Kinase active. Interacts with PDLIM4; when
FT                   associated with E-307 and F-419."
FT                   /evidence="ECO:0000269|PubMed:19307596"
FT   MUTAGEN         307
FT                   /note="P->E: Kinase active. Interacts with PDLIM4; when
FT                   associated with E-302 and F-419."
FT                   /evidence="ECO:0000269|PubMed:19307596"
FT   MUTAGEN         419
FT                   /note="Y->F: Loss of kinase activity. Loss of interaction
FT                   with PDLIM4."
FT                   /evidence="ECO:0000269|PubMed:19307596"
FT   STRAND          87..93
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   STRAND          99..102
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   STRAND          110..114
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   STRAND          118..126
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   TURN            127..129
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   STRAND          132..136
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   HELIX           137..139
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   STRAND          140..142
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   HELIX           146..148
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   STRAND          152..154
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   HELIX           158..165
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   STRAND          167..170
FT                   /evidence="ECO:0007829|PDB:1SHD"
FT   STRAND          174..179
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   STRAND          181..183
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   STRAND          187..195
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   TURN            196..198
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   STRAND          199..209
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   STRAND          211..213
FT                   /evidence="ECO:0007829|PDB:2SRC"
FT   STRAND          215..218
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   STRAND          221..225
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   HELIX           226..233
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   STRAND          240..242
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   STRAND          256..259
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   HELIX           267..269
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   STRAND          270..278
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   STRAND          280..282
FT                   /evidence="ECO:0007829|PDB:6ATE"
FT   STRAND          283..289
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   TURN            290..292
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   STRAND          293..299
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   TURN            302..304
FT                   /evidence="ECO:0007829|PDB:2BDF"
FT   HELIX           307..319
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   STRAND          328..332
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   STRAND          334..336
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   STRAND          338..341
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   STRAND          345..348
FT                   /evidence="ECO:0007829|PDB:6ATE"
FT   HELIX           349..353
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   HELIX           355..358
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   HELIX           363..382
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   HELIX           392..394
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   STRAND          395..397
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   HELIX           399..401
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   STRAND          403..405
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   HELIX           410..413
FT                   /evidence="ECO:0007829|PDB:2SRC"
FT   HELIX           417..420
FT                   /evidence="ECO:0007829|PDB:2SRC"
FT   TURN            423..426
FT                   /evidence="ECO:0007829|PDB:1Y57"
FT   HELIX           429..431
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   HELIX           434..439
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   HELIX           444..459
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   TURN            460..462
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   HELIX           471..479
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   HELIX           492..501
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   HELIX           506..508
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   HELIX           512..520
FT                   /evidence="ECO:0007829|PDB:1FMK"
FT   TURN            521..523
FT                   /evidence="ECO:0007829|PDB:1FMK"
SQ   SEQUENCE   536 AA;  59835 MW;  C1908084683E5DE8 CRC64;
     MGSNKSKPKD ASQRRRSLEP AENVHGAGGG AFPASQTPSK PASADGHRGP SAAFAPAAAE
     PKLFGGFNSS DTVTSPQRAG PLAGGVTTFV ALYDYESRTE TDLSFKKGER LQIVNNTEGD
     WWLAHSLSTG QTGYIPSNYV APSDSIQAEE WYFGKITRRE SERLLLNAEN PRGTFLVRES
     ETTKGAYCLS VSDFDNAKGL NVKHYKIRKL DSGGFYITSR TQFNSLQQLV AYYSKHADGL
     CHRLTTVCPT SKPQTQGLAK DAWEIPRESL RLEVKLGQGC FGEVWMGTWN GTTRVAIKTL
     KPGTMSPEAF LQEAQVMKKL RHEKLVQLYA VVSEEPIYIV TEYMSKGSLL DFLKGETGKY
     LRLPQLVDMA AQIASGMAYV ERMNYVHRDL RAANILVGEN LVCKVADFGL ARLIEDNEYT
     ARQGAKFPIK WTAPEAALYG RFTIKSDVWS FGILLTELTT KGRVPYPGMV NREVLDQVER
     GYRMPCPPEC PESLHDLMCQ CWRKEPEERP TFEYLQAFLE DYFTSTEPQY QPGENL
//
